Anti-PD-l1 antibodies and uses thereof

Novel anti-PD-L1 antibodies with high affinity and enhanced T cell activation capabilities address the need for better PD-L1 inhibition, effectively treating tumors and infectious diseases.

JP2024164038AActive Publication Date: 2024-11-26INNOVENT BIOLOGICS (SUZHOU) CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024125864
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-12-19
Filing Date
2024-08-01
Publication Date
2024-11-26
Estimated Expiration
2038-12-27

AI Technical Summary

Technical Problem

There is a need for novel anti-PD-L1 antibodies that bind better to PD-L1 and have good druggability, as existing antibodies may not effectively inhibit PD-L1 activity and enhance immune responses against tumors.

Method used

Development of antibody molecules that specifically bind to PD-L1 with high affinity, enhance T cell function, and inhibit PD-L1 activity, including bispecific or multispecific antibodies and immunoconjugates, which can be used alone or in combination with other therapies.

Benefits of technology

The antibodies effectively enhance T cell activation, increase tumor-infiltrating lymphocytes, and inhibit cancer progression, offering improved therapeutic efficacy against tumors and infectious diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164038000001_ABST
    Figure 2024164038000001_ABST
Patent Text Reader

Abstract

To provide a novel anti-PD-L1 antibody that binds better to PD-L1 and has good druggability.SOLUTION: The present invention provides antibodies and antibody fragments that specifically bind to PD-L1, compositions comprising the antibodies or antibody fragments, nucleic acids encoding the antibodies or antibody fragments, corresponding host cells and uses thereof. In addition, certain therapies using combinations of the antibodies and antibody fragments with other therapies are provided.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to novel antibodies and antibody fragments thereof that specifically bind to PD-L1, and compositions comprising the antibodies or antibody fragments. Additionally, the present invention relates to nucleic acids encoding the antibodies or antibody fragments thereof, host cells comprising the nucleic acids, and related uses. Furthermore, the present invention relates to therapeutic and diagnostic uses of these antibodies and antibody fragments. In particular, the present invention relates to combination therapy of these antibodies and antibody fragments with other therapies, e.g., therapeutic methods or drugs. [Background technology]

[0002] Programmed death-ligand 1 (PD-L1) is a protein involved in suppressing immune system responses during chronic infections, pregnancy, tissue allografts, autoimmune diseases, and cancer. PD-L1 regulates immune responses by binding to an inhibitory receptor called programmed cell death 1 (PD-1) expressed on the surface of T cells, B cells, and monocytes. PD-L1 also negatively regulates T cell function through interaction with another receptor, B7.1 (also known as B7-1 or CD80). The formation of PD-L1 / PD-1 and PD-L1 / B7.1 complexes negatively regulates T cell receptor signaling, subsequently resulting in downregulation of T cell activation and inhibition of antitumor immune activity. PD-L1 is overexpressed in many cancers, including various solid tumors such as bladder tumors, breast tumors, colon tumors, lung tumors, melanoma, ovarian tumors, salivary tumors, gastric tumors, and thyroid tumors. Overexpression of PD-L1 on tumor cells can promote tumor invasion and is often associated with a poor prognosis.

[0003] Therefore, there is still a need in the art for novel anti-PD-L1 antibodies that bind better to PD-L1 and have good druggability. Summary of the Invention

[0004] Disclosed herein are antibody molecules that bind to PD-L1. Nucleic acids encoding the antibodies or antibody fragments thereof, as well as expression vectors, host cells, and methods for producing the antibody molecules are also provided. Also provided are anti-PD-L1 antibody molecules, immunoconjugates comprising multispecific or bispecific antibody molecules, and pharmaceutical compositions. The anti-PD-L1 antibody molecules disclosed herein can be used alone or in combination with other therapies, e.g., therapeutic agents or treatments, to treat, prevent, and / or diagnose neoplastic and infectious diseases. Additionally, disclosed herein are compositions and methods for detecting PD-L1, as well as methods for preventing or treating various diseases, including neoplastic and / or infectious diseases, using the anti-PD-L1 antibody molecules.

[0005] Thus, in some embodiments, the antibodies or fragments thereof of the invention bind (specifically) to PD-L1, hi some embodiments, the antibodies or fragments thereof of the invention bind (specifically) to human PD-L1.

[0006] In some embodiments, the anti-PD-L1 antibodies, or fragments thereof, of the invention bind to PD-L1 (e.g., human PD-L1) with high affinity, for example, an equilibrium dissociation constant (K ) of less than about 50 nM to PD-L1, preferably about 20 nM or less, more preferably about 15 nM or less, more preferably about 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, or 2 nM or less, and most preferably about 1.5 nM, 1.4 nM, 1.3 nM, 1.2 nM, 1.1 nM, 1 nM, 0.9 nM, or 0.8 nM or less. D In some embodiments, the anti-PD-L1 antibodies of the invention bind to PD-L1 with a K of 0.1-10 nM, preferably 0.5-10 nM, more preferably 0.6-10 nM, 0.7-8 nM, and 0.7-5 nM, and most preferably 0.5-1.5 nM, 0.7-1.5 nM, and 0.7-1 nM. DIn some embodiments, the PD-L1 is human PD-L1. In some embodiments, the binding affinity of the antibody is determined using biological optical interferometry (e.g., Fortebio affinity assay).

[0007] In some embodiments, the antibodies or fragments thereof of the invention have an EC of about 4 nM, 3.5 nM, 3 nM, 2.9 nM, 2.8 nM, 2.7 nM, 2.6 nM, 2.5 nM, 2.4 nM, 2.3 nM, 2.2 nM, 2.1 nM, 2 nM, 1.9 nM, 1.8 nM, 1.7 nM, or 1.6 nM or less on cells expressing human PD-L1. 50 In some embodiments, the binding is determined using flow cytometry (e.g., FACS). In some embodiments, the cells expressing human PD-L1 are CHO cells expressing human PD-L1.

[0008] In some embodiments, the antibodies or fragments thereof of the invention inhibit PD-L1-related activity with an EC of about 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, or 0.7 nM or less, preferably 0.1-1 nM, 0.5-1 nM, 0.6-1 nM, 0.6 nM, 0.7 nM, 0.8 nM, 0.9 nM, or 1 nM. 50 In some embodiments, the relevant activity of PD-L1 is binding of PD-L1 to PD-1. In some embodiments, the antibody or fragment thereof of the invention blocks PD-L1 binding to PD-1 in an MOA assay with an EC of about 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, or 0.7 nM or less, preferably 0.1-1 nM, 0.5-1 nM, 0.6-1 nM, 0.6 nM, 0.7 nM, 0.8 nM, 0.9 nM, or 1 nM. 50 In some embodiments, the cell is a CHO cell.

[0009] In some embodiments, the antibodies or fragments thereof of the invention enhance T cell function. In some embodiments, the antibodies or fragments thereof of the invention enhance T cell proliferation. In some embodiments, the antibodies or fragments thereof of the invention enhance IFN-γ secretion. In some embodiments, the antibodies or fragments thereof of the invention enhance IL-2 secretion. In some embodiments, the antibodies or fragments thereof of the invention enhance both IFN-γ and IL-2 secretion. In some embodiments, the enhancement is determined by mixed lymphocyte reaction (MLR). In some embodiments, the ability of the antibodies or fragments thereof to activate T cells is better than known anti-PD-L1 antibodies, such as Tecentriq.

[0010] In some embodiments, the antibodies or fragments thereof of the present invention have lower viscosity and therefore better druggability than known anti-PD-L1 antibodies (e.g., Tecentriq). In some embodiments, the antibodies or fragments thereof of the present invention have a retention time (RT) of about 10 minutes, about 9 minutes, or less than about 8 minutes, preferably about 7-9 minutes, preferably about 7-8.5 minutes, about 7.5-8.5 minutes, about 7-8 minutes, or about 7.5-8 minutes, for example, about 7.5 minutes, 7.6 minutes, 7.7 minutes, 7.8 minutes, 7.9 minutes, 8 minutes, 8.1 minutes, 8.2 minutes, 8.3 minutes, 8.4 minutes, 8.5 minutes, in Zenix column chromatography.

[0011] In some embodiments, the antibodies or fragments thereof of the invention inhibit one or more activities of PD-L1, for example, causing one or more of the following: an increase in tumor-infiltrating lymphocytes, an increase in T cell receptor-mediated proliferation, or a decrease in immune evasion of cancer cells.

[0012] In some embodiments, the anti-PD-L1 antibodies, or fragments thereof, of the invention are capable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC).

[0013] In some embodiments, the anti-PD-L1 antibodies of the invention, alone or in combination with other therapies (e.g., therapeutic modalities and / or agents), are effective in treating a tumor (e.g., cancer) or an infection (e.g., a chronic infection). In some embodiments, the tumor is a tumor immune escape. In some embodiments, the tumor is a cancer. In some embodiments, the tumor is a gastrointestinal tumor. In some embodiments, the cancer is colon cancer.

[0014] In some embodiments, the heavy chain and / or light chain of the anti-PD-L1 antibodies, or fragments thereof, of the invention further comprise a signal peptide sequence, such as METDTLLLWVLLLWVPGSTG (SEQ ID NO:68).

[0015] In some embodiments, the antibodies of the present invention also include amino acid sequence variants of the anti-PD-L1 antibodies, as well as antibodies that bind to the same epitope as any of the above-mentioned anti-PD-L1 antibodies or fragments thereof.

[0016] In some embodiments, the anti-PD-L1 antibodies of the invention further comprise a human or mouse constant region. In some embodiments, the anti-PD-L1 antibodies of the invention are in the form of an IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, or IgE antibody. In some embodiments, the anti-PD-L1 antibodies of the invention comprise a heavy chain constant region selected from the group consisting of, for example, an IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE heavy chain constant region; in particular, a heavy chain constant region selected from the group consisting of, for example, an IgG1, IgG2, IgG3, and IgG4 heavy chain constant region, more particularly, an IgG1 or IgG4 heavy chain constant region, for example, a human IgG1 or IgG4 heavy chain constant region. In one embodiment, the heavy chain constant region is a human IgG1 or human IgG4 heavy chain constant region. In some embodiments, the murine constant region comprised in the anti-PD-L1 antibodies of the invention is selected from the group consisting of IgG1, IgG2A, IgG2B, and IgG3.

[0017] In another embodiment, the anti-PD-L1 antibody molecule of the invention comprises a light chain constant region chosen from, e.g., a kappa or lambda light chain constant region, preferably a kappa (e.g., human kappa) light chain constant region.

[0018] In another embodiment, the anti-PD-L1 antibody molecule comprises a heavy chain constant region of IgG4 (e.g., human IgG4). In one embodiment, the human IgG4 comprises a substitution at position 228 according to EU numbering (e.g., Ser to Pro). In another embodiment, the human IgG4 comprises a mutation at AA 114-115 (EU numbering) (Armour KL1, Clark MR, Hadley AG, Williamson LM, Eur J Immunol., Aug., 1999; 29(8):2613-24, Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities). In another embodiment, the anti-PD-L1 antibody molecule comprises a heavy chain constant region of IgG1 (e.g., human IgG1). In one embodiment, the human IgG1 comprises a substitution at position 297 according to EU numbering (e.g., Asn to Ala). In one embodiment, the human IgG1 comprises a substitution at position 265 according to EU numbering, a substitution at position 329 according to EU numbering, or both (e.g., a substitution of Asp to Ala at position 265 according to EU numbering and / or a substitution of Pro to Ala at position 329 according to EU numbering). In one embodiment, the human IgG1 comprises a substitution at position 234 according to EU numbering, a substitution at position 235 according to EU numbering, or both (e.g., a substitution of Leu to Ala at position 234 according to EU numbering and / or a substitution of Leu to Ala at position 235 according to EU numbering). In one embodiment, the heavy chain constant region comprises or consists of the amino acid sequence set forth in SEQ ID NO: 64, 65, or 66, or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto.

[0019] In another embodiment, the anti-PD-L1 antibody molecule comprises a κ light chain constant region, such as a human κ light chain constant region. In one embodiment, the light chain constant region comprises or consists of an amino acid sequence set forth in SEQ ID NO:67, or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto.

[0020] In one embodiment, the anti-PD-L1 antibody molecule comprises an IgG1 heavy chain constant region (e.g., a human IgG1 heavy chain constant region) and a κ light chain constant region (e.g., a human κ light chain constant region). In one embodiment, the human IgG1 comprises a substitution at position 297 according to EU numbering (e.g., an Asn to Ala substitution). In some embodiments, the IgG1 heavy chain constant region comprises or consists of an amino acid sequence set forth in SEQ ID NO: 64 or 65, or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto. In one embodiment, the human κ light chain constant region comprises or consists of the amino acid sequence set forth in SEQ ID NO:67, or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto.

[0021] In another embodiment, the anti-PD-L1 antibody molecule comprises an IgG4 heavy chain constant region (e.g., a human IgG4 heavy chain constant region) and a κ light chain constant region (e.g., a human κ light chain constant region). In one embodiment, the constant region is a mutated IgG4 constant region, such as a mutated human IgG4 constant region (e.g., having a mutation at 228 according to EU numbering, e.g., an S228P mutation, and / or having a mutation at AA 114-115 (EU numbering)). In some embodiments, the IgG4 heavy chain constant region comprises or consists of an amino acid sequence as set forth in SEQ ID NO:66, or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto. In one embodiment, the human κ light chain constant region comprises or consists of the amino acid sequence set forth in SEQ ID NO:67, or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto.

[0022] In one embodiment, the anti-PD-L1 antibody molecule is isolated or recombinant.

[0023] In some embodiments, the anti-PD-L1 antibody is a monoclonal or monospecific antibody. The anti-PD-L1 antibody molecule may also be a humanized, chimeric, or human antibody molecule. In some embodiments, the anti-PD-L1 antibody is a chimeric antibody. In some embodiments, the anti-PD-L1 antibody is a humanized antibody. In some embodiments, the anti-PD-L1 antibody is a human antibody. In some embodiments, at least a portion of the framework sequences of the anti-PD-L1 antibody are human consensus framework sequences. In one embodiment, the anti-PD-L1 antibody of the invention also comprises an antibody fragment thereof, preferably an antibody fragment selected from the group consisting of Fab, Fab', Fab'-SH, Fv, single chain variable fragment (e.g., scFv) or (Fab')2, single domain antibody, diabody (dAb), or linear antibody.

[0024] In some embodiments, the anti-PD-L1 antibody molecule is in the form of a bispecific or multispecific antibody molecule. In one embodiment, the bispecific antibody molecule has a first binding specificity for PD-L1 and a second binding specificity for LAG-3. In one embodiment, the bispecific antibody molecule binds to PD-L1 and LAG-3. A multispecific antibody molecule may have any combination of binding specificities for PD-L1 and other targets.

[0025] In one embodiment, the invention provides a nucleic acid encoding any of the above anti-PD-L1 antibodies or fragments thereof. In one embodiment, a vector comprising the nucleic acid is provided. In one embodiment, the vector is an expression vector. In one embodiment, a host cell comprising the nucleic acid or vector is provided. In one embodiment, the host cell is eukaryotic. In another embodiment, the host cell is selected from a yeast cell, a mammalian cell (e.g., a CHO cell or a 293 cell), or other cell suitable for the preparation of an antibody or antigen-binding fragment thereof. In another embodiment, the host cell is a prokaryote, such as an E. coli cell.

[0026] In one embodiment, the invention provides a method for preparing an anti-PD-L1 antibody or fragment thereof (preferably an antigen-binding fragment), which comprises incubating a host cell under conditions suitable for expression of a nucleic acid encoding the antibody or fragment thereof (preferably an antigen-binding fragment), and optionally isolating the antibody or fragment thereof (preferably an antigen-binding fragment).In certain embodiments, the method further comprises recovering the anti-PD-L1 antibody or fragment thereof (preferably an antigen-binding fragment) from the host cell.

[0027] In some embodiments, the invention provides an immunoconjugate comprising any of the anti-PD-L1 antibodies provided herein and another agent, such as a cytotoxic agent or a marker. In some embodiments, the immunoconjugate is used to prevent or treat a tumor (e.g., cancer) or an infectious disease. In some embodiments, the tumor is a tumor immune escape tumor. Preferably, the tumor is a gastrointestinal tumor (e.g., cancer), such as colon cancer. Preferably, the infectious disease is a chronic infection.

[0028] In some embodiments, the invention provides a composition comprising an anti-PD-L1 antibody or fragment thereof (preferably an antigen-binding fragment), or immunoconjugate thereof described herein, preferably the composition is a pharmaceutical composition. In one embodiment, the composition further comprises a pharmaceutical auxiliary material. In one embodiment, the composition, e.g., the pharmaceutical composition, comprises a combination of an anti-PD-L1 antibody or fragment thereof of the invention, or an immunoconjugate thereof, and one or more other therapeutic agents (e.g., a chemotherapeutic agent, another antibody, a cytotoxic agent, a vaccine, an effective anti-infective agent, or an immunomodulatory agent, e.g., an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule).

[0029] In some embodiments, the pharmaceutical composition is used to prevent or treat a tumor (e.g., cancer) or an infection. In some embodiments, the tumor is a tumor immune escape. Preferably, the tumor is a gastrointestinal tumor (e.g., cancer), e.g., colon cancer. Preferably, the infectious disease is a chronic infectious disease. In other aspects, the invention relates to a method for preventing or treating a tumor (e.g., cancer) or an infectious disease in a subject or individual, comprising administering to the subject an effective amount of any of the anti-PD-L1 antibodies or fragments thereof, pharmaceutical compositions, or immunoconjugates described herein. In some embodiments, the tumor is a tumor immune escape. In one embodiment, the tumor is a gastrointestinal tumor (e.g., cancer), e.g., colon cancer. In one embodiment, the infectious disease is a chronic infectious disease. In other aspects, the invention also relates to the use of any of the anti-PD-L1 antibodies or fragments thereof described herein for the preparation of a medicament for treating a tumor (e.g., cancer) or an infection in a subject. In some embodiments, the tumor is a tumor immune escape. In one embodiment, the tumor is a gastrointestinal tumor (e.g., cancer), e.g., colon cancer. In one embodiment, the infectious disease is a chronic infection.

[0030] In some further embodiments, the methods of prevention or treatment described herein further comprise administering one or more therapies (e.g., therapeutic and / or other therapeutic agents) to the subject or individual. In some embodiments, the therapeutic agent comprises surgical therapy and / or radiation therapy. In some embodiments, the other therapeutic agent is selected from the group consisting of chemotherapeutic agents, cytotoxic agents, vaccines, active anti-infective agents, other antibodies, and immunomodulatory agents (e.g., costimulatory molecule activators or immune checkpoint molecule inhibitors).

[0031] In some embodiments, the subject or individual is a non-human animal, e.g., a mammal, preferably a human.

[0032] In one aspect, the invention relates to a method for detecting PD-L1 in a sample, comprising: (a) contacting the sample with any of the anti-PD-L1 antibodies or fragments thereof described herein; and (b) detecting formation of a complex between the anti-PD-L1 antibody or fragment thereof and PD-L1. In one embodiment, the anti-PD-L1 antibody is detectably labeled.

[0033] In some embodiments, the invention relates to a kit or article of manufacture comprising an anti-PD-L1 antibody or fragment thereof described herein. In some embodiments, the kit or article of manufacture comprises an anti-PD-L1 antibody or fragment thereof described herein and optional ancillary pharmaceutical materials. In some embodiments, the kit or article of manufacture further comprises instructions for administering the agent to treat a tumor or infection.

[0034] The present invention also encompasses any combination of any of the embodiments described herein. Any of the embodiments described herein or any combination thereof may be applicable to any of the anti-PD-L1 antibodies or fragments thereof, methods and uses of the invention described herein. [Brief description of the drawings]

[0035] [Figure 1] Figure 1 shows the binding of anti-PD-L1 antibodies of the invention to CHO-PDL1 cells as determined by FACS. [Diagram 2] Figure 2 shows the binding of anti-PD-L1 antibodies of the invention to CHO-PDL1 cells as determined by FACS. [Diagram 3] FIG. 3 shows the blocking activity of antibodies of the invention against PD-1 / PD-L1 interaction as determined by MOA assay. [Figure 4A] 4A and 4B show activation of T cells by antibodies of the invention (relative expression of IL-2) as determined by MLR assay. [Figure 4B]4A and 4B show activation of T cells by antibodies of the invention (relative expression of IL-2) as determined by MLR assay. [Figure 5A] 5A and 5B show activation of T cells by antibodies of the invention (relative expression of IFN-γ) as determined by MLR assay. [Figure 5B] 5A and 5B show activation of T cells by antibodies of the invention (relative expression of IFN-γ) as determined by MLR assay. [Figure 6] FIG. 6 shows the inhibitory effect of the antibody of the invention on tumors. [Figure 7] FIG. 7 shows the inhibitory effect of an antibody of the invention in combination with an anti-LAG-3 antibody. Description of the Invention

[0036] Abbreviation Unless otherwise specified, the abbreviations used in this specification have the following meanings. The following abbreviations are used: ADCC antibody-dependent cell-mediated cytotoxicity CDC Complement-dependent cytotoxicity CDR Complementarity determining region of the variable region of an immunoglobulin CHO Chinese hamster ovary EC 50 Concentration that results in 50% efficacy or binding K D equilibrium dissociation constant ELISA Enzyme-Linked Immunosorbent Assay FACS Fluorescence Activated Cell Sorting MOA Mechanism of Action MLR mixed lymphocyte reaction FR antibody framework region I C 50 Concentration that produces 50% inhibition Ig immunoglobulins The immunoglobulin alignment and numbering system established by Elvin A. Kabat ((1991) Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, Md.) mAb / Mab / MAb Monoclonal Antibody PCR Polymerase Chain Reaction IFN Interferon VL Light chain variable region VH Heavy chain variable region LC light chain HC heavy chain HCDR Heavy chain complementarity determining region LCDR light chain complementarity determining region

[0037] definition Before describing the invention in detail below, it should be understood that the invention is not limited to the specific methodology, protocols, and reagents described herein, as these may vary. It should also be understood that the terms used herein are for the purpose of describing specific embodiments only, and are not intended to limit the scope of the invention, which is limited only by the appended claims. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0038] For purposes of describing the present specification, the following definitions will be used, and where applicable, terms used in the singular may also include the plural and vice versa. It will be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0039] The term "about" when used in conjunction with a numerical value is intended to encompass a range of numerical values ​​from a lower limit of 5% below the stated numerical value to an upper limit of 5% above the stated numerical value.

[0040] "Affinity" refers to the strength of the sum of all non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity, which represents a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y is generally expressed as the equilibrium dissociation constant (K D Affinity can be expressed as: Affinity is known in the art and can be measured by common methods known in the art, including those described herein.

[0041] The term "programmed cell death 1 ligand 1", "PD-L1", "programmed cell death ligand 1", "cluster of differentiation 274", "CD274", or "B7 homolog 1", as used herein, refers to any native PD-L1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term encompasses "full-length", unprocessed PD-L1, and any form of PD-L1 that results from processing within the cell. PD-L1 may exist as a transmembrane protein or a soluble protein. The term also encompasses naturally occurring variants of PD-L1, such as splice variants or allelic variants. The basic structure of PD-L1 includes four domains: an extracellular Ig-like V-type domain and an Ig-like C2-type domain, a transmembrane domain, and a cytoplasmic domain. Further information regarding the human PD-L1 gene, including the genomic DNA sequence, can be found at NCBI Gene ID No. 29126. Further information regarding the human PD-L1 gene, including the genomic DNA sequence, can be found at NCBI Gene ID No. 60533. The amino acid sequence of an exemplary full-length human PD-L1 protein can be found, for example, at NCBI Accession No. NP_001254653 or UniProt Accession No. Q9NZQ7, and the sequence of an exemplary full-length mouse PD-L1 protein can be found, for example, at NCBI Accession No. NP_068693 or Uniprot Accession No. Q9EP73.

[0042] The terms "anti-PD-L1 antibody", "anti-PD-L1", "PD-L1 antibody" or "PD-L1 binding antibody", as used herein, refer to an antibody, or fragment thereof, that can bind to PD-L1 protein with sufficient affinity. In one embodiment, the extent to which an anti-PD-L1 antibody binds to a non-PD-L1 protein is less than or greater than about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% of the extent to which the antibody binds to the PD-L1 protein as measured, for example, by radioimmunoassay (RIA) or biophotonic interference assay or MSD assay.

[0043] As used herein, "monoclonal antibody" or "mAb" or "Mab" refers to a single copy or clone of an antibody, e.g., derived from a eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. Monoclonal antibodies or antigen-binding fragments thereof can be produced, for example, by hybridoma technology, recombinant technology, phage display technology, synthetic techniques such as CDR grafting, or a combination of such techniques or other techniques known in the art.

[0044] "Native antibodies" refer to naturally occurring immunoglobulin molecules of various structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, consisting of two identical light chains and two identical heavy chains linked by disulfide bonds. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also called the variable heavy domain or the heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL), also called the variable light domain or the light chain variable domain, followed by a constant light domain (CL). The light chain of an antibody can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain. A "native sequence Fc region" comprises an amino acid sequence identical to that of an Fc region found in nature. Native-sequence human Fc regions include native-sequence human IgG1 Fc regions (non-A and A allotypes), native-sequence human IgG2 Fc regions, native-sequence human IgG3 Fc regions, and native-sequence human IgG4 Fc regions, and naturally occurring variants of the above.

[0045] "Antibody fragment" refers to a molecule that comprises a portion of an intact antibody and binds to the antigen to which the intact antibody binds, but is distinct from the intact antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibodies (e.g., scFv); single domain antibodies; bivalent or bispecific antibodies or fragments thereof; camelid antibodies; and bispecific or multispecific antibodies formed from said antibody fragments.

[0046] As used herein, the term "epitope" refers to a portion of an antigen (e.g., human PD-L1) that specifically interacts with an antibody molecule. Such a portion (referred to herein as an antigenic determinant) generally comprises or is a portion of an element such as an amino acid side chain or a sugar side chain. An antigenic determinant can be defined using methods known in the art or disclosed herein (e.g., by crystallography or hydrogen-deuterium exchange). At least one or several portions of an antibody molecule that specifically interact with an antigenic determinant are generally located within a CDR. Generally, an epitope has specific three-dimensional structural characteristics. Generally, an epitope has specific charge characteristics. Some epitopes are linear epitopes and others are conformational epitopes.

[0047] An "antibody that binds to the same or overlapping epitope" as a reference antibody refers to an antibody that blocks 50%, 60%, 70%, 80%, 90%, or 95% or more of the binding of the reference antibody to its antigen in a competitive assay, or conversely, the reference antibody blocks 50%, 60%, 70%, 80%, 90%, or 95% or more of the binding of the antibody to its antigen in a competitive assay.

[0048] An antibody that competes with a reference antibody for binding to its antigen refers to an antibody that blocks 50%, 60%, 70%, 80%, 90%, or 95% or more of the binding of the reference antibody to its antigen in a competitive assay. Conversely, the reference antibody blocks 50%, 60%, 70%, 80%, 90%, or 95% or more of the binding of the antibody to its antigen in a competitive assay. Many types of competitive binding assays can be used to determine whether an antibody competes with another antibody, such as direct or indirect solid-phase radioimmunoassay (RIA), direct or indirect solid-phase enzyme immunoassay (EIA), sandwich competition assay (see, for example, Stahli et al., 1983, Methods in Enzymology 9:242-253).

[0049] An antibody that inhibits (e.g., competitively inhibits) the binding of a reference antibody to its antigen refers to an antibody that inhibits 50%, 60%, 70%, 80%, 90%, or 95% or more of the binding of the reference antibody to its antigen. Conversely, the reference antibody inhibits 50%, 60%, 70%, 80%, 90%, or 95% or more of the binding of the antibody to its antigen. The binding of an antibody to its antigen can be measured by affinity (e.g., equilibrium dissociation constant). Methods for determining affinity are known in the art.

[0050] An antibody that exhibits the same or similar binding affinity and / or specificity as a reference antibody refers to an antibody that may have at least 50%, 60%, 70%, 80%, 90%, or 95% or more of the binding affinity and / or specificity of the reference antibody, which may be determined by any method known in the art for determining binding affinity and / or specificity.

[0051] "Complementarity determining regions" or "CDR regions" or "CDRs" are regions of antibody variable domains that exhibit high sequence variability, form structurally defined loops ("hypervariable loops") and / or comprise antigen contact residues ("antigen contact points"). CDRs are primarily responsible for binding to an epitope. Heavy and light chain CDRs are generally referred to as CDR1, CDR2, and CDR3, and are numbered sequentially from the N-terminus. The CDRs located in the variable domain of an antibody heavy chain are referred to as HCDR1, HCDR2, and HCDR3, and the CDRs located in the variable domain of an antibody light chain are referred to as LCDR1, LCDR2, and LCDR3. For a given amino acid sequence of a light chain variable region or a heavy chain variable region, the precise amino acid sequence boundaries of each CDR can be determined, for example, by the methods of Chothia (Chothia et al. (1989) Nature 342:877-883; Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273:927-948 (1997)), which are based on the three-dimensional structure of the antibody and the topology of the CDR loops; Kabat (Kabat et al., Sequences of Proteins of Immunological Interest, 4th ed., US Department of Health and Human Services, National Institutes of Health (1987)), which are based on antibody sequence variation; AbM (University of Bath), Contact (University College London), the International ImMunoGeneTics database (IMGT) (imgt.cines.fr / on the World Wide Web), and the North American Standards Association (ANSA), which are based on affinity propagation clustering using a large number of crystal structures. The CDR definitions may be determined using any one or combination of a number of well-known antibody CDR assignment systems.

[0052] For example, according to various CDR determination schemes, the residues for each CDR are as follows:

[0053] [Table 1]

[0054] CDRs can also be determined based on having the same Kabat numbering position as a reference CDR sequence (eg, any of the exemplary CDRs of the invention).

[0055] Unless otherwise specified, in the present invention, the term "CDR" or "CDR sequence" also encompasses CDR sequences determined by any of the above methods.

[0056] Unless otherwise specified, in the present invention, when referring to the positions of antibody variable region residues (including heavy chain variable region residues and light chain variable region residues), it refers to the numbered positions according to the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).

[0057] In one embodiment, the boundaries of the CDRs of an antibody of the invention are determined by the Chothia rules or the Kabat rules, eg, for antibodies whose sequences are shown in Table 1.

[0058] It should be noted that the boundaries of the CDRs of the variable regions of antibodies obtained by different allocation systems may be different. That is, the CDR sequences of the variable regions of antibodies defined by different allocation systems are different. Thus, when it comes to defining an antibody having a specific CDR sequence defined in the present invention, the scope of the antibody also includes antibodies whose variable region sequences comprise that specific CDR sequence, but when a different protocol (e.g., different allocation system rules or a combination thereof) is applied, a different CDR boundary is claimed from the specific CDR boundary as defined in the present invention.

[0059] Antibodies with different specificities (i.e., different binding sites for different antigens) have different CDRs (under the same allocation system). However, although CDRs differ from antibody to antibody, only a limited number of amino acid positions in the CDRs are directly involved in antigen binding. At least two of the Kabat, Chothia, AbM, Contact, and North methods can be used to determine the minimum overlapping region, resulting in a "minimum binding unit" for antigen binding. This minimum binding unit can be a subpart of the CDR. As will be apparent to those skilled in the art, the remaining residues of the CDR sequence can be determined by antibody structure and protein folding. Thus, the present invention contemplates any variant of the CDRs shown herein. For example, in a CDR variant, the amino acid residues in the minimum binding unit may remain unchanged, while other CDR residues defined by Kabat or Chothia may be replaced by conservative amino acid residues.

[0060] Five major classes of antibodies are known in the art: IgA, IgD, IgE, IgG, and IgM, and several of these classes can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0061] "Antibody of IgG form" refers to the IgG form to which the heavy chain constant region of the antibody belongs. The heavy chain constant regions of all antibodies of the same type are identical, while the heavy chain constant regions of antibodies of different types are different. For example, an antibody of IgG1 form refers to the Ig domain of its heavy chain constant region being the Ig domain of IgG1.

[0062] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which secreted immunoglobulins that bind to Fc receptors (FcRs) present on certain cytotoxic cells (e.g., NK cells, neutrophils, and macrophages) enable cytotoxic effector cells to specifically bind antigen-bearing target cells and subsequently kill those target cells with cytotoxins. NK cells, the primary cells mediating ADCC, express only FcyRIII, whereas monocytes express FcyRI, FcyRII, and FcyRIII. Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-92 (1991), summarizes FcR expression on cells of the hematopoietic lineage. To assess the ADCC activity of the molecule of interest, in vitro ADCC assays such as those described in U.S. Patent No. 5,500,362 or 5,821,337, or 6,737,056 (Presta) can be carried out. Useful effector cells for such assays include PBMCs and NK cells. Optionally / alternatively, the ADCC activity of the molecule of interest can be assessed in vivo, for example in an animal model such as that disclosed in Clynes et al., PNAS (USA) 95:652-656 (1998).

[0063] The term "cytotoxic agent" or "cytotoxic factor" as used herein refers to a substance that inhibits or suppresses cell function and / or causes cell death or destruction. Examples of cytotoxic agents include those disclosed in WO2015 / 153513, WO2016 / 028672, WO2015 / 138920, and WO2016 / 007235.

[0064] The term "therapeutic agent", as used herein, encompasses any agent effective in the prevention or treatment of tumors (e.g., cancer) and infectious diseases (e.g., chronic infections), including chemotherapeutic agents, cytotoxic agents, vaccines, other antibodies, active anti-infective agents, immunomodulatory agents, such as any of the agents disclosed in WO2016 / 007235 or WO2010 / 077634 or US60 / 696426 that can be used in combination with an anti-PD-L1 antibody.

[0065] "Chemotherapeutic agents" include chemical compounds useful in the treatment of cancer. Examples of chemotherapeutic agents include those disclosed in WO2016 / 007235, WO2010 / 077634, US60 / 696426 or WO2016 / 061142, US61 / 264061, or WO2016 / 007235.

[0066] The term "cytokine" is a general term for proteins that are released by a cell population and act as intercellular mediators for other cells. Examples of such cytokines include lymphokines and monokines; interleukins (IL), such as IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, and IL-15; tumor necrosis factors, such as TNF-α or TNF-β; and LIF and other polypeptide factors, including Kit ligand (KL) and gamma-interferon. As used herein, the term cytokine includes biologically active equivalents of native sequence cytokines, including proteins from natural sources or recombinant cell cultures, as well as small molecule entities produced by artificial synthesis, and pharmacologically acceptable derivatives and salts thereof.

[0067] The term "costimulatory molecule" refers to a relevant binding partner that specifically binds to a costimulatory ligand on a T cell, thus enabling a T cell-mediated costimulatory response (such as, but not limited to, proliferation). Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are required for efficient immune responses. Costimulatory molecules include, but are not limited to: MHC class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activation molecules (SLAM proteins), NK cell activating receptors, BTLA, Toll ligand receptors, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a / CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1 ), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, V LA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD1 8, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CE These include ligands that specifically bind to ACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, CD19a, and CD83.

[0068] The term "activator" or "agonist" includes a substance that increases a particular parameter (e.g., activity) of a molecule (e.g., a costimulatory molecule). For example, the term includes a substance that increases the activity (e.g., costimulatory activity) of a molecule by at least 5%, 10%, 25%, 50%, 75%, or more.

[0069] The term "immune checkpoint molecules" refers to a group of molecules on the cell surface of CD4 T cells and CD8 T cells. These molecules can effectively act as "brakes" to downregulate or suppress antitumor immune responses. Immune checkpoint molecules include, but are not limited to, programmed cell death receptor 1 (PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), B7H1, B7H4, OX-40, CD137, CD40, and LAG-3, which directly inhibit immune cells.

[0070] The term "inhibitor" or "antagonist" includes a substance that reduces a particular parameter (e.g., activity) of a molecule (e.g., an immune checkpoint inhibitor protein). For example, the term includes a substance that inhibits the activity of a molecule (e.g., LAG-3 activity) by at least 5%, 10%, 20%, 30%, 40% or more. Thus, the inhibitory effect need not be 100%.

[0071] The term "diabody" refers to an antibody fragment having two antigen-binding sites, which comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) linked in one polypeptide chain (VH-VL). The use of a short linker between the two domains in each chain forces these domains to pair with complementary domains in the other chain to form two antigen-binding sites. Diabodies can be bivalent or bispecific. Diabodies are described in more detail, for example, in EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993). Tribodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).

[0072] A "functional Fc region" has an "effector function" of a native sequence Fc region. Exemplary "effector functions" include C1q binding, CDC, Fc receptor binding, ADCC, phagocytosis, cell surface receptor (e.g., B cell receptor, or BCR) downregulation, and the like. Such effector functions generally require that the Fc region be associated with a binding domain (e.g., an antibody variable domain) and can be assessed using a variety of assays, such as those disclosed herein.

[0073] "Effector function" refers to a biological activity that can be attributed to an antibody Fc region and varies depending on the antibody isotype. Examples of antibody effector functions include C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, cell surface receptor (e.g., B cell receptor) down-regulation, and B cell activation.

[0074] "Human effector cells" refers to leukocytes that express one or more FcRs and perform effector function. In certain embodiments, these cells express at least FcyRIII and perform the effector function of ADCC. Examples of human leukocytes that mediate ADCC include peripheral blood mononuclear cells (PBMCs), natural killer (NK) cells, monocytes, cytotoxic T cells, and neutrophils. Effector cells can be isolated from their native source, such as blood.

[0075] The term "effective amount" refers to the amount or dose of the antibody or fragment or conjugate or composition of the present invention that produces the expected effect in a patient in need of treatment or prevention after administration to the patient in one or more doses. The effective amount can be easily determined by the attending physician as a person skilled in the art by considering various factors such as: the species, such as a mammal; its size, age, and health condition; the specific disease involved; the extent or severity of the disease; the response of the individual patient; the specific antibody administered; the route of administration; the bioavailability characteristics of the formulation administered; the selected dosing regimen; and the use of concurrent therapy.

[0076] A "therapeutically effective amount" refers to an amount effective to achieve a desired therapeutic result at the required dosage for a desired period of time. A therapeutically effective amount of an antibody or antibody fragment, or a conjugate or composition thereof, may vary according to various factors, such as the individual's condition, age, sex, and weight, and the ability of the antibody or antibody portion to elicit a desired response in the individual. A therapeutically effective amount is also an amount in which the toxic or undesired effects of the antibody or antibody fragment, or a conjugate or composition thereof, are less than the therapeutically beneficial effects. A "therapeutically effective amount" preferably inhibits a measurable parameter (e.g., tumor growth rate) by at least about 20%, more preferably at least about 40%, even more preferably at least about 50%, 60%, or 70%, and even more preferably at least about 80% or 90% compared to untreated subjects. The ability of a compound to inhibit a measurable parameter (e.g., cancer) can be evaluated in an animal model system predictive of efficacy in human tumors. Optionally, such properties of a composition can also be evaluated by examining the inhibitory ability of the compound to be measurable in vitro by assays known to the skilled artisan.

[0077] A "prophylactically effective amount" refers to an amount effective to achieve the desired prophylactic result, at the necessary dosage, for the desired period of time. Generally, since a prophylactic dose is administered to a subject prior to an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

[0078] "Antibodies and antigen-binding fragments thereof" suitable for the present invention include, but are not limited to, polyclonal, monoclonal, monovalent, bispecific, heteroconjugate, multispecific, recombinant, heterologous, heterohybrid, chimeric, humanized (especially CDR-grafted), deimmunized, or human antibodies, Fab fragments, Fab' fragments, F(ab')2 fragments, fragments generated from a Fab expression library, Fd, Fv, disulfide-stabilized Fv (dsFv), single-chain antibodies (e.g., scFv), diabodies or tetrabodies (Holliger P. et al. (1993) Proc. Natl. Acad. Sci. USA 90 (14), 6444-6448), nanobodies (also called single domain antibodies), anti-idiotypic (anti-Id) antibodies (including, for example, anti-Id antibodies against an antibody of the present invention), and epitope-binding fragments of any of the above.

[0079] The "Fab" fragment contains the heavy and light chain variable domains, and also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH1 domain, including one or more cysteines from the antibody hinge region. Fab'-SH refers to Fab' in which the cysteine ​​residues of the constant domains bear a free thiol group. F(ab')2 antibody fragments were originally produced as paired Fab' fragments with hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

[0080] The term "Fc region" is used herein to define a C-terminal region of an immunoglobulin heavy chain comprising at least a portion of a constant region. This term includes Fc regions and native sequence variant Fc regions. In certain embodiments, a human IgG heavy chain Fc region extends from Cys226 or Pro230 to the carbonyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified, the numbering of amino acid residues in the Fc region or constant region is based on the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0081] The term "variable region" or "variable domain" refers to the domain of the heavy or light chain of an antibody that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies often have similar structures, with each domain containing four conserved framework regions (FR) and three complementarity determining regions (CDR) (see, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co. p91 (2007)). A single VH or VL domain is sufficient to provide antigen-binding specificity. In addition, the VH or VL domain derived from an antibody that binds to a specific antigen can be used to isolate an antibody that binds to the antigen, to screen a library of complementary VL or VH domains, respectively. See, for example, Portolano et al., J. Immunol., 150:880-887 (1993); Clarkson et al., Nature, 352:624-628 (1991).

[0082] "Framework" or "FR" refers to variable domain residues other than the complementarity determining region CDR residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Thus, the CDR and FR sequences are generally found in a heavy chain variable domain (VH) (or a light chain variable domain (VL)) of the following sequence: FR1-HCDR1(LCDR1)-FR2-HCDR2(LCDR2)-FR3-HCDR3(LCDR3)-FR4.

[0083] Unless otherwise specified, the numbering of the residues in the various domains of the antibody is based on the EU numbering system, referred to as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Science Health, Bethesda, MD, 1991.

[0084] The terms "full length antibody," "complete antibody," and "intact antibody" are used interchangeably herein to refer to an antibody having a structure substantially similar to a native antibody structure or an antibody having a heavy chain that contains an Fc region as defined herein.

[0085] An "Fv" is the smallest antibody fragment that contains an intact antigen-binding site. In one embodiment, a two-chain Fv format consists of one heavy-chain variable domain and one light-chain variable domain as a tightly non-covalently linked dimer. In a single-chain Fv (scFv) format, one heavy-chain variable domain and one light-chain variable domain can be covalently linked via a flexible peptide linker such that the light and heavy chains can associate in a structure similar to the "dimeric" structure of the two-chain format. In this configuration, it is the three CDRs of each variable domain that define an antigen-binding site on the surface of the VH-VL dimer. In summary, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (i.e., only half of an Fv with three CDRs specific for an antigen) still has the ability to recognize and bind antigen, although with a lower affinity than an intact binding site. For a review of scFvs, see, e.g., Pluckthun in The Pharmacology of Monoclonal Antibodies, Vol. 113, edited by Rosenburg and Moore, (Springer-Verlag, New York, 1994), pages 269-315.

[0086] The terms "host cell", "host cell line" and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid is introduced, including generations of such cells. Host cells include "transformants" and "transformed cells", including the primary transformed cell and generations derived therefrom, regardless of the number of passages. Generations may not be completely identical in nucleic acid content to the parent cell and may contain mutations. Included herein are mutant generations that have the same function or biological activity as screened or selected from the originally transformed cell.

[0087] "Human antibody" refers to an antibody having an amino acid sequence that corresponds to the amino acid sequence of an antibody produced by a human or human cell, or derived from a non-human source that utilizes a human antibody library or other human antibody coding sequence. This definition of a human antibody specifically excludes humanized antibodies, which contain non-human antigen-binding residues.

[0088] "Human consensus framework" refers to a framework that represents the most frequently occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is a selection from a subtype of variable domain sequences. Generally, the subtype of the sequence is a subtype disclosed in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., NIH Public Publication 91-3242, Bethesda MD (1991), vols. 1-3. In one embodiment, for the VL, the subtype is subtype kappa I as in Kabat et al. (see above). In one embodiment, for the VH, the subtype is subtype III as in Kabat et al. (see above).

[0089] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human CDRs and amino acid residues from human FRs. In some embodiments, a humanized antibody comprises substantially all of at least one, and generally two, variable domains, in which all or substantially all of the CDRs (e.g., CDRs) correspond to the CDRs of a non-human antibody and all or substantially all of the FRs correspond to the FRs of a human antibody. A humanized antibody may also optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody (e.g., a non-human antibody) refers to an antibody that has been humanized.

[0090] The terms "cancer" and "cancerous" generally refer to or refer to a physiological disorder in mammals characterized by uncontrolled cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More specific examples of such cancers include, but are not limited to, squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), lung cancer (including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma), peritoneal cancer, hepatocellular carcinoma, gastric cancer (including gastrointestinal and gastrointestinal stromal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, urinary tract cancer, liver tumor, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, anal cancer, cystic cancer, thyroid ... Included are stem cell carcinoma, melanoma, superficial diffuse melanoma, lentigo maligna melanoma, acral melanoma, nodular melanoma, multiple myeloma and B-cell lymphoma, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, chronic myeloid leukemia, and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal blood vessel proliferation with nevus diseases, edema (e.g., associated with brain tumors), and Meigs syndrome, brain tumors and cancers, and head and neck cancers, and associated metastases. In certain embodiments, cancers suitable for treatment with the antibodies of the invention include non-small cell lung cancer, squamous cell carcinoma, small cell lung cancer, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatocellular carcinoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, leukemia, and head and neck cancer, including metastatic forms of these cancers.

[0091] The terms "cell proliferative disorder" and "proliferative disorder" refer to disorders associated with a particular degree of abnormal cell proliferation. In one embodiment, a cell proliferative disorder refers to cancer.

[0092] The term "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms "cancer," "cancerous," "cell proliferative disorder," "proliferative disorder," and "tumor" are not mutually exclusive as referred to herein.

[0093] The term "infectious disease" refers to a disease caused by a pathogen, including, for example, a viral infection, a bacterial infection, a fungal infection, or a protozoan, such as a parasitic infection.

[0094] The term "tumor immune evasion" refers to tumors evading immune recognition and clearance. Thus, as a therapeutic concept, tumor immunity is "treated" and when evasion is weakened, tumors are recognized and attacked by the immune system. Examples of tumor recognition include tumor binding, tumor regression, and tumor clearance.

[0095] The term "chronic infection" refers to an infection in which an infectious agent (e.g., a pathogen, e.g., a virus, a bacterium, a protozoan such as a parasite, a fungus, etc.) induces an immune response in the infected host, but is not cleared or eliminated from the host as in acute infections. Chronic infections can be persistent, latent, or delayed. While acute infections are generally resolved by the immune system within days or weeks (e.g., influenza), persistent infections can continue at relatively low levels for months, years, decades, or a lifetime (e.g., hepatitis B). In contrast, latent infections are characterized by long periods of asymptomatic activity, punctuated by occasionally rapidly increasing hyperinfections and elevated pathogen levels (e.g., herpes simplex). Finally, delayed infections are characterized by a slow and continuous progression of disease symptoms, such as a long latency period, followed by a prolonged and progressive clinical course after the onset of clinical symptoms. Unlike latent and persistent infections, chronic infections may not begin with an acute phase of viral proliferation (e.g., picornavirus infections, visna virus, scrapie, Creutzfeldt-Jakob disease). Exemplary infectious agents that may induce chronic infections include viruses (e.g., cytomegalovirus, Epstein-Barr virus, hepatitis B virus, hepatitis C virus, herpes simplex virus types I and II, human immunodeficiency virus types 1 and 2, human papillomavirus, human T-lymphotropic virus types 1 and 2, varicella-zoster virus, etc.), bacteria (e.g., Mycobacterium tuberculosis ( Mycobacterium Tuberculosis ), Listeria ( Listeria ) species, Klebsiella pneumoniae ( Klebsiella Pneumonia ), Streptococcus pneumoniae ( Streptococcus Pneumonia ), Staphylococcus aureus ( Staphylococcus aureus ), Borrelia species, Helicobacter pylori ( Helicobacter pylori ), parasites (e.g., Leishmania ( Leishmania ) species, Plasmodium falciparum ( Plasmodium falciparum ), Schistosoma ( Schistosoma ) species, Toxoplasma ( Toxoplasma ) species, Trypanosoma ( Trypanosoma ) species, Taenia craciceps ( Taenia carssiceps ) and fungi (e.g., Aspergillus ( Aspergillus ) species, Candida albicans ( Candida albicans ), Coccidioides immitis ( Coccidioides Immunity ), Histoplasma capsulatum ( Histoplasma Capsulatum ), Pneumocystis carinii ( Pneumocystis carinii ) and other diseases. Additional infectious agents include prions or misfolded proteins that affect brain or neuronal structures by further increasing protein misfolding in the brain or neuronal tissue, leading to the formation of amyloid plaques that result in cell death, tissue damage, and ultimately death. Examples of diseases caused by prion infections include Creutzfeldt-Jakob disease and its variants, Gerstmann-Sträussler-Scheinker syndrome (GSS), fatal familial insomnia (sFI), kuru, scrapie, bovine spongiform encephalopathy (BSE) (also known as "mad cow" disease), and various other encephalopathies in various animal types (e.g., transmissible mink encephalopathy (TME), chronic wasting disease (CWD) in white-tailed deer, moose, and New Zealand deer, feline spongiform encephalopathy, exoticungulate encephalopathy (EUE) in nyala, oryx, and kudu, and spongiform encephalopathy in ostriches).

[0096] An "immunoconjugate" is an antibody conjugated to one or more other substances, including, but not limited to, a cytotoxic agent or a label.

[0097] The term "label" as used herein refers to a compound or composition that is directly or indirectly conjugated or fused to an agent such as a polynucleotide probe or an antibody, and that facilitates the detection of the conjugated or fused agent. The label may be detectable itself (e.g., a radioisotope label or a fluorescent label) or, in the case of an enzymatic label, may catalyze a chemical change of a detectable substrate compound or composition. This term is intended to encompass direct labeling of a probe or antibody by coupling (i.e., physically binding) the probe or antibody with a detectable substance, and indirect labeling of a probe or antibody by reacting with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody with a fluorescently labeled secondary antibody, and end-labeling of a biotinylated DNA probe such that it can be detected with fluorescently labeled streptavidin.

[0098] An "individual" or "subject" includes a mammal. Mammals include, but are not limited to, domestic animals (e.g., cows, goats, cats, dogs, and horses), primates (e.g., humans and non-human primates, such as monkeys), rabbits, and rodents (e.g., mice and rats). In some embodiments, the individual or subject is a human.

[0099] An "isolated" antibody is one that has been separated from a component of its natural environment. In some embodiments, the antibody is purified to greater than 95% or 99% purity, for example, as determined by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr., B848:79-87 (2007).

[0100] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. Isolated nucleic acid includes a nucleic acid molecule that is contained in a cell that ordinarily contains the nucleic acid molecule, but that is present extrachromosomally or in a chromosomal location that is different from its natural chromosomal location.

[0101] An "isolated nucleic acid encoding an anti-PD-L1 antibody, or fragment thereof" refers to one or more nucleic acid molecules encoding the antibody heavy or light chain (or fragment thereof), and includes such nucleic acid molecules in a single vector or separate vectors, and including such nucleic acid molecules present in one or more locations within a host cell.

[0102] The terms "nucleic acid", "nucleic acid sequence", "nucleotide sequence" or "polynucleotide sequence" and "polynucleotide" are used interchangeably. They refer to nucleotides of any length (deoxyribonucleotides or ribonucleotides) in a polymeric or analogous form. A polynucleotide may be single-stranded or double-stranded, and if single-stranded, may be the coding strand or the non-coding (antisense) strand. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides may be intercalated with non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. A nucleic acid may be a recombinant polynucleotide, or a polynucleotide that is non-naturally occurring or linked in a non-natural layout to other polynucleotides from genomic, cDNA, semi-synthetic, or synthetic sources.

[0103] The terms "polypeptide," "peptide," and "protein" (when single chain) are used interchangeably herein to refer to amino acid polymers of any length. The polymers may be linear or branched, may comprise modified amino acids, and may be interrupted by non-amino acids. The terms also include amino acid polymers that have been modified (e.g., by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component). Polypeptides may be isolated from natural sources, produced from eukaryotic or prokaryotic hosts by recombinant techniques, or may be the product of synthetic methods.

[0104] Calculations of sequence identity between sequences are performed as follows.

[0105] To determine the percent identity of two amino acid sequences or two nucleic acid sequences, these sequences are aligned for optimal comparison (e.g., for optimal alignment, gaps can be introduced into the first and second amino acid sequences or into one or both nucleic acid sequences, or non-homologous sequences can be truncated for comparison). In a preferred embodiment, the length of the aligned reference sequence for comparison is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at the corresponding amino acid positions or nucleotide positions are then compared. If a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at this position.

[0106] A mathematical algorithm can be used to accomplish the sequence comparison and calculation of percent identity between two sequences. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the GAP program of the GCG software package, Needlema and Wunsch [(1970) J. Mol. Biol., 48:444-453], with a Blossom 62 matrix or a PAM250 matrix and gap weights of 16, 14, 12, 10, 8, 6, or 4 and length weights of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide acid sequences is determined using the GAP program of the GCG software package (available at http: / / www.gcg.com), with a NWSgapdna.CMP matrix and gap weights of 40, 50, 60, 70, or 80 and length weights of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and which should be used unless otherwise specified) is a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5, with a Blossom 62 scoring matrix.

[0107] The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17), as incorporated into the ALIGN program (version 2.0), using a PAM120 weighted remainder table, a gap length penalty of 12, and a gap penalty of 4.

[0108] Additionally or alternatively, the nucleic acid and protein sequences described herein can also be used as a "query sequence" to perform searches against public databases, for example, to identify other family member sequences or related sequences. For example, such searches can be performed using the NBLAST and XBLAST programs of Altschul et al., (1990) J. Mol. Biol., 215:403-10. To obtain nucleotide sequences homologous to the nucleic acid molecules of the present invention, BLAST nucleotide searches can be performed using the NBLAST program, score=100, word length=12. To obtain amino acid sequences homologous to the protein molecules of the present invention, BLAST protein searches can be performed using the XBLAST program, score=50, word length=3. To obtain gapped alignment results for comparison, gapped BLAST can be used as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402. BLAST and Gapped BLAST programs, the default parameters of each program (eg, XBLAST and NBLAST) can be used. See http: / / www.ncbi.nlm.nih.gov.

[0109] As used herein, the term "hybridization under low stringency, medium stringency, high stringency, or extreme stringency conditions" refers to hybridization and washing conditions. Instructions for carrying out hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6, which are incorporated by reference. Aqueous and non-aqueous methods are described in these references, and either method can be used. The specific hybridization conditions described herein are as follows: 1) low stringency hybridization conditions are about 45°C in 6× sodium chloride / sodium citrate (SSC), followed by two washes in 0.2×SSC, 0.1% SDS at at least 50°C (for low stringency conditions, the temperature of the washes can be increased to 55°C); 2) medium stringency hybridization conditions are about 45°C in 6×SSC, followed by one or more washes in 0.2×SSC, 0.1% SDS at about 60° C.; 3) high stringency hybridization conditions are in 6×SSC at about 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 65° C.; and preferably, 4) extreme stringency hybridization conditions are in 0.5 M sodium phosphate, 7% SDS at 65° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 65° C. Extreme stringency conditions (4) are the preferred conditions and are the ones to be used unless otherwise specified.

[0110] The term "pharmaceutical composition" refers to such a composition that is present in a form that permits the biological activity of the active ingredients contained therein to be effective and that does not contain additional ingredients that are unacceptably toxic to the subject to which the composition is administered.

[0111] The term "pharmaceutical auxiliary material" refers to a diluent, adjuvant (eg, Freund's adjuvant (complete and incomplete)), excipient, carrier, stabilizer, or the like, administered with an active substance.

[0112] As used herein, "treatment" (or "treat" or "treating") refers to slowing, interrupting, halting, relieving, halting, reducing, or reversing the progression or severity of an existing symptom, disorder, condition, or disease.

[0113] As used herein, "prevention" (or "prevent" or "preventing") includes inhibiting the onset or progression of a disease or disorder or symptoms of a particular disease or disorder. In some embodiments, subjects with a family history of cancer are candidates for a preventative regimen. In general, with respect to cancer, the term "prevention" refers to the administration of a drug before signs or symptoms of cancer develop, particularly in subjects at risk of cancer.

[0114] The term "anti-infective" includes any molecule that specifically inhibits or eliminates the growth of a microorganism, such as a virus, a bacterium, a fungus, or a protozoan, e.g., a parasite, and is not lethal to the host at the concentration and interval of administration. As used herein, the term anti-infective includes antibiotics, antibacterial agents, antiviral agents, antifungal agents, and antiprotozoal agents. In one particular embodiment, the anti-infective is non-toxic to the host at the concentration and interval of administration.

[0115] Antibacterial anti-infectives or antimicrobials can be broadly classified as bactericidal (i.e., directly kill) or bacteriostatic (i.e., prevent division). Antibacterial anti-infectives can be further classified as narrow-spectrum antibacterials (i.e., act only on limited bacterial subtypes, such as gram-negative) or broad-spectrum antibacterials (i.e., act on a wide range of species). Examples include amikacin, gentamicin, geldanamycin, herbimycin, mupirocin, furantoin, pyrazinamide, quinupristin / dalfopristin, rifampicin / rifampin, isoniazid and pyrazinamide tablets, or tinidazole.

[0116] The term "antiviral agent" includes any agent that inhibits or eliminates viral growth, pathogenicity, and / or survival, including, for example, acyclovir, cidofovir, zidovudine, didanosine (ddI, VIDEX), zalcitabine (ddC, HIVID), stavudine (d4T, ZERIT), lamivudine (3TC, Epivir), abacavir (ZIAGEN), emtricitabine (Emtriva), and the like.

[0117] The term "antifungal agent" includes any substance that inhibits or eliminates the growth, virulence, and / or survival of fungi, including, for example, natamycin, rimocidin, filipin, nystatin, amphotericin B, candicin, patchouli, neem seed oil, coconut oil, and the like.

[0118] The term "antiprotozoal drug" includes any substance that inhibits or eliminates the growth, pathogenicity, and / or survival of a protozoal organism (e.g., a parasite). Examples of antiprotozoal drugs include antimalarial drugs such as quinine, quinidine, etc.

[0119] For exemplary antibacterial, antiviral, antifungal, and antiprotozoal agents, see, e.g., WO2010 / 077634.

[0120] For anti-infectives, see also, for example, WO2014 / 008218, WO2016 / 028672, WO2015 / 138920 or WO2016 / 061142.

[0121] The term "vector," as used herein, refers to a nucleic acid molecule capable of amplifying other nucleic acids to which it is linked. The term includes vectors that act as autonomously replicating nucleic acid structures as well as vectors that integrate into the genome of a host cell into which they are introduced. Some vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression" vectors.

[0122] "Subject / patient sample" refers to a collection of cells or bodily fluids obtained from a patient or subject. The source of the tissue or cell sample can be solid tissue, e.g., fresh, frozen and / or preserved organ or tissue samples or biopsy or puncture samples; blood or blood components; bodily fluids such as cerebrospinal fluid, amniotic fluid, peritoneal fluid, or interstitial fluid; cells obtained from a subject at any time during pregnancy or development. Tissue samples can comprise compounds that are not naturally mixed with the tissue, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, etc. Examples of tumor samples include, but are not limited to, tumor biopsies, fine needle aspirates, bronchial washings, pleural fluid, saliva, urine, surgical specimens, circulating tumor cells, serum, plasma, circulating plasma proteins, ascites, primary cell cultures or cell lines derived from tumors or exhibiting tumor-like properties, and archived tumor samples, such as formalin-fixed, paraffin-embedded tumor samples, or frozen tumor samples.

[0123] The term "package insert" is used to refer to instructions typically included in commercial packages of therapeutic products, which contain information about the indications, usage, dosage, administration, concomitant therapy, contraindications and / or warnings concerning the application of such therapeutic product.

[0124] Antibodies of the Invention Thus, in some embodiments, the antibodies or fragments thereof of the invention bind to PD-L1. In some embodiments, the antibodies or fragments thereof of the invention bind to mammalian PD-L1, e.g., human PD-L1. For example, the antibody molecule specifically binds to an epitope (e.g., a linear or conformational epitope) of PD-L1. In some embodiments, the antibody molecule binds to one or more extracellular domains of PD-L1.

[0125] In some embodiments, the anti-PD-L1 antibodies, or fragments thereof, of the invention have one or more of the following characteristics: (1) The anti-PD-L1 antibodies, or fragments thereof, of the present invention bind to PD-L1 (e.g., human PD-L1) with high affinity, e.g., bind to PD-L1 with an equilibrium dissociation constant (K ) of less than about 50 nM, preferably about 20 nM or less, more preferably about 15 nM or less, more preferably about 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, or 2 nM or less, and most preferably about 1.5 nM, 1.4 nM, 1.3 nM, 1.2 nM, 1.1 nM, 1 nM, 0.9 nM, or 0.8 nM or less. D In some embodiments, the anti-PD-L1 antibodies of the invention bind to PD-L1 with a K of 0.1-10 nM, preferably 0.5-10 nM, more preferably 0.6-10 nM, 0.7-8 nM, and 0.7-5 nM, and most preferably 0.5-1.5 nM, 0.7-1.5 nM, and 0.7-1 nM. D In some embodiments, the PD-L1 is human PD-L1. In some embodiments, the binding affinity of the antibody is determined using biological optical interferometry (e.g., Fortebio affinity assay).

[0126] (2) The antibody or fragment thereof of the present invention has an EC of about 4 nM, 3.5 nM, 3 nM, 2.9 nM, 2.8 nM, 2.7 nM, 2.6 nM, 2.5 nM, 2.4 nM, 2.3 nM, 2.2 nM, 2.1 nM, 2 nM, 1.9 nM, 1.8 nM, 1.7 nM, or 1.6 nM or less in cells expressing human PD-L1. 50 In some embodiments, the binding is determined using flow cytometry (e.g., FACS). In some embodiments, the cells expressing human PD-L1 are CHO cells expressing human PD-L1.

[0127] (3) The antibody or fragment thereof of the present invention inhibits PD-L1-related activity with an EC of, for example, about 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, or 0.7 nM or less, preferably 0.1 to 1 nM, 0.5 to 1 nM, 0.6 to 1 nM, 0.6 nM, 0.7 nM, 0.8 nM, 0.9 nM, or 1 nM. 50In some embodiments, the relevant activity of PD-L1 is binding of PD-L1 to PD-1. In some embodiments, the antibody or fragment thereof of the invention blocks PD-L1 binding to PD-1 in an MOA assay with an EC of about 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, or 0.7 nM or less, preferably 0.1-1 nM, 0.5-1 nM, 0.6-1 nM, 0.6 nM, 0.7 nM, 0.8 nM, 0.9 nM, or 1 nM. 50 In some embodiments, the cell is a CHO cell.

[0128] (4) the ability of the antibody or fragment thereof of the present invention to enhance T cell function is better than known anti-PD-L1 antibodies, such as Tecentriq.

[0129] (5) the ability of the antibody of the invention or a fragment thereof to activate T cells, e.g., in an MLR, is better than known anti-PD-L1 antibodies, such as Tecentriq.

[0130] (6) The ability of the antibody of the invention or a fragment thereof to enhance IFN-γ secretion, e.g., in an MLR, is better than known anti-PD-L1 antibodies, e.g., Tecentriq.

[0131] (7) The ability of the antibody of the invention or a fragment thereof to enhance IL-2 secretion, e.g., in an MLR, is better than known anti-PD-L1 antibodies, such as Tecentriq.

[0132] (8) The antibody or fragment thereof of the present invention has a lower viscosity than known anti-PD-L1 antibodies (e.g., Tecentriq) and therefore has better druggability. In some embodiments, the antibody or fragment thereof of the present invention has a retention time (RT) of about 10 minutes, about 9 minutes, or less than about 8 minutes, preferably about 7 to 9 minutes, preferably about 7 to 8.5 minutes, about 7.5 to 8.5 minutes, about 7 to 8 minutes, or about 7.5 to 8 minutes, for example, about 7.5 minutes, 7.6 minutes, 7.7 minutes, 7.8 minutes, 7.9 minutes, 8 minutes, 8.1 minutes, 8.2 minutes, 8.3 minutes, 8.4 minutes, 8.5 minutes, in Zenix column chromatography.

[0133] (9) The antibody or fragment thereof of the present invention inhibits one or more activities of PD-L1, resulting in, for example, one or more of the following: an increase in tumor-infiltrating lymphocytes, an increase in T cell receptor-mediated proliferation, or a decrease in immune evasion of cancer cells.

[0134] (10) The anti-PD-L1 antibodies or fragments thereof of the present invention can induce antibody-dependent cell-mediated cytotoxicity (ADCC).

[0135] In some embodiments, the anti-PD-L1 antibodies, or antigen-binding fragments thereof, of the invention have one or more of the following characteristics: (i) exhibits the same or similar binding affinity and / or specificity for PD-L1 as an antibody of the invention (e.g., any of the antibodies listed in Table 3); (ii) inhibits (e.g., competitively inhibits) the binding of an antibody of the invention (e.g., any of the antibodies listed in Table 3) to PD-L1; (iii) binds to the same or overlapping epitope as an antibody of the invention (e.g., any of the antibodies listed in Table 3); (iv) competes for binding to PD-L1 with an antibody of the invention (e.g., any of the antibodies listed in Table 3); (v) has one or more biological characteristics of an antibody of the invention (e.g., any of the antibodies listed in Table 3).

[0136] Exemplary Antibodies In some embodiments, the anti-PD-L1 antibodies, or antigen-binding fragments thereof, of the invention comprise a heavy chain variable region (VH), wherein the VH is (i) the three complementarity determining regions (CDRs) contained in the VH of any of the antibodies listed in Table B; or (ii) a sequence comprising a total of at least one, and at most 5, 4, 3, 2 or 1 amino acid mutation (preferably an amino acid substitution, preferably a conservative substitution) in the three CDR regions compared to the sequence of (i); The present invention relates to a method for producing a semiconductor device comprising the steps of:

[0137] In some embodiments, the anti-PD-L1 antibodies, or antigen-binding fragments thereof, of the invention comprise a light chain variable region (VL), wherein the VL is (i) the three complementarity determining regions (CDRs) contained in the VL of any of the antibodies listed in Table B; or (ii) a sequence comprising a total of at least one, and at most 5, 4, 3, 2 or 1 amino acid mutation (preferably an amino acid substitution, preferably a conservative substitution) in the three CDR regions compared to the sequence of (i); The present invention relates to a method for producing a semiconductor device comprising the steps of:

[0138] In some embodiments, the anti-PD-L1 antibodies, or antigen-binding fragments thereof, of the invention comprise a heavy chain variable domain, VH, and a light chain variable domain, VL, wherein: (a) VH is (i) the three complementarity determining regions (CDRs) contained in the VH of any of the antibodies listed in Table B; or (ii) a sequence comprising a total of at least one, and at most 5, 4, 3, 2 or 1 amino acid mutation (preferably an amino acid substitution, preferably a conservative substitution) in the three CDR regions compared to the sequence of (i); and / or (b) VL is (i) the three complementarity determining regions (CDRs) contained in the VL of any of the antibodies listed in Table B; or (ii) a sequence comprising a total of at least one, and at most 5, 4, 3, 2 or 1 amino acid mutation (preferably an amino acid substitution, preferably a conservative substitution) in the three CDR regions compared to the sequence of (i); The present invention relates to a method for producing a semiconductor device comprising the steps of:

[0139] In a preferred embodiment, the VH comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO:26, 27, 28, 29, 30, or 31.

[0140] In a preferred embodiment, the VL comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO:32, 33, 34, 35, 36, or 37.

[0141] In a preferred embodiment, the anti-PD-L1 antibodies, or antigen-binding fragments thereof, of the invention comprise: (i) three HCDRs of a heavy chain variable region as set forth in SEQ ID NO: 26 or 30 and three LCDRs of a light chain variable region as set forth in SEQ ID NO: 32 or 36; or (ii) three HCDRs of a heavy chain variable region as set forth in SEQ ID NO: 27 and three LCDRs of a light chain variable region as set forth in SEQ ID NO: 33; or (iii) three HCDRs of a heavy chain variable region as set forth in SEQ ID NO: 28 and three LCDRs of a light chain variable region as set forth in SEQ ID NO: 34; or (iv) three HCDRs of a heavy chain variable region represented by SEQ ID NO: 29 or 31 and three LCDRs of a light chain variable region represented by SEQ ID NO: 35 or 37 The present invention relates to a method for producing a semiconductor device comprising the steps of:

[0142] In some embodiments, the anti-PD-L1 antibodies, or antigen-binding fragments thereof, of the invention comprise a heavy chain variable region (VH) and / or a light chain variable region (VL), in which: (i) the VH comprises complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3, where HCDR1 comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, or 4, or HCDR1 comprises an amino acid sequence having one, two, or three mutations (preferably, amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, or 4; HCDR2 comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 5, 6, 7, 8, or 9, or HCDR HCDR2 comprises an amino acid sequence having one, two or three mutations (preferably amino acid substitutions, preferably conservative substitutions) compared to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 7, 8 or 9; HCDR3 comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 11, 12 or 13, or HCDR3 comprises an amino acid sequence having one, two or three mutations (preferably amino acid substitutions, preferably conservative substitutions) compared to an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 11, 12 or 13; and / or (ii) the VL comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3, wherein LCDR1 comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 14, 15, or 16, or LCDR1 comprises an amino acid sequence having one, two, or three mutations (preferably amino acid substitutions, preferably conservative substitutions) compared to an amino acid sequence selected from the group consisting of SEQ ID NO: 14, 15, or 16; LCDR2 comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 17, 18, 19, or 20, or LCDR3 comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 18, 19, or 21, DR2 comprises an amino acid sequence having one, two or three mutations (preferably amino acid substitutions, preferably conservative substitutions) compared to an amino acid sequence selected from the group consisting of SEQ ID NO: 17, 18, 19 or 20; LCDR3 comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 21, 22, 23, 24 or 25, or LCDR3 comprises an amino acid sequence having one, two or three mutations (preferably amino acid substitutions, preferably conservative substitutions) compared to an amino acid sequence selected from the group consisting of SEQ ID NO: 21, 22, 23, 24 or 25.

[0143] In a preferred embodiment, the present invention provides an antibody comprising a heavy chain variable region (VH) and / or a light chain variable region (VL), wherein: (a) VH is (i) a combination of HCDR1, HCDR2, and HCDR3 as shown in Table A; or (ii) A variant of the HCDR combination of (i), comprising a total of at least one, and at most five, four, three, two, or one amino acid mutation (preferably an amino acid substitution, preferably a conservative substitution) in the three CDR regions. and / or (b) VL is (i) a combination of LCDR1, LCDR2 and LCDR3 shown in Table A; or (ii) A variant of the LCDR combination of (i), comprising a total of at least one, and at most 5, 4, 3, 2 or 1 amino acid mutation (preferably an amino acid substitution, preferably a conservative substitution) in the three CDR regions. The present invention provides an anti-PD-L1 antibody, or antigen-binding fragment thereof, comprising:

[0144] In a preferred embodiment, the invention provides an anti-PD-L1 antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), where the VH comprises complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3, and the VL comprises CDRs LCDR1, LCDR2, and LCDR3, and the combinations of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 contained in the antibody or antigen-binding fragment thereof are as shown in the table below (Table A).

[0145] [Table 2]

[0146] In some embodiments, the anti-PD-L1 antibodies, or antigen-binding fragments thereof, of the invention comprise a heavy chain variable domain, VH, and / or a light chain variable domain, VL, in which: (a) the heavy chain variable region VH is (i) comprising or consisting of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence selected from SEQ ID NOs: 26, 27, 28, 29, 30, or 31; (ii) comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 27, 28, 29, 30, or 31; or (iii) comprises an amino acid sequence having one or more (preferably at most 10, more preferably at most 5, 4, 3, 2 or 1) amino acid mutations (preferably amino acid substitutions, more preferably conservative amino acid substitutions) compared to an amino acid sequence selected from SEQ ID NOs: 26, 27, 28, 29, 30, or 31, and preferably these amino acid mutations are not present within the CDRs; and / or (b) the light chain variable region VL is (i) comprises or consists of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence selected from SEQ ID NOs: 32, 33, 34, 35, 36, or 37; (ii) comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 32, 33, 34, 35, 36, or 37; or (iii) comprises an amino acid sequence having one or more (preferably at most 10, more preferably at most 5, 4, 3, 2 or 1) amino acid mutations (preferably amino acid substitutions, more preferably conservative amino acid substitutions) compared to an amino acid sequence selected from SEQ ID NO: 32, 33, 34, 35, 36, or 37, and preferably these amino acid mutations are not present within the CDRs.

[0147] In a preferred embodiment, the invention provides an anti-PD-L1 antibody or antigen-binding fragment thereof comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), where the combination of heavy chain variable domain VH and light chain variable domain VL contained in the antibody or antigen-binding fragment thereof is shown in the table below (Table B).

[0148] [Table 3]

[0149] In some embodiments, the anti-PD-L1 antibodies, or antigen-binding fragments thereof, of the invention comprise a heavy chain and / or a light chain, wherein: (a) the heavy chain is (i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence selected from SEQ ID NOs: 38, 39, 40, 41, 42, 43, 44, or 45; (ii) comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 39, 40, 41, 42, 43, 44, or 45; or (iii) comprises an amino acid sequence having one or more (preferably at most 20 or 10, more preferably at most 5, 4, 3, 2 or 1) amino acid mutations (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to an amino acid sequence selected from SEQ ID NOs: 38, 39, 40, 41, 42, 43, 44 or 45, preferably these amino acid mutations are not present in the CDRs of the heavy chain, more preferably these amino acid mutations are not present in the heavy chain variable region; and / or (b) the light chain is (i) comprises or consists of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence selected from SEQ ID NOs: 46, 47, 48, 49, 50, or 51; (ii) comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 46, 47, 48, 49, 50, or 51; or (iii) comprises an amino acid sequence having one or more (preferably at most 20 or 10, more preferably at most 5, 4, 3, 2 or 1) amino acid mutations (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to an amino acid sequence selected from SEQ ID NO: 46, 47, 48, 49, 50 or 51, and preferably, these amino acid mutations are not present in the light chain CDRs, and more preferably, these amino acid mutations are not present in the light chain variable region.

[0150] In a preferred embodiment, the invention provides an anti-PD-L1 antibody or antigen-binding fragment thereof comprising a heavy chain and a light chain, the heavy and light chain combinations contained in the antibody or antigen-binding fragment thereof are shown in the Table below (Table C).

[0151] [Table 4]

[0152] In some embodiments, the heavy chain and / or light chain of the anti-PD-L1 antibodies, or fragments thereof, of the invention further comprise a signal peptide sequence, such as METDTLLLWVLLLWVPGSTG (SEQ ID NO:68).

[0153] In one embodiment of the invention, the amino acid mutations described herein include amino acid substitutions, insertions or deletions. Preferably, the amino acid mutations described herein are amino acid substitutions, preferably conservative substitutions.

[0154] In a preferred embodiment, the amino acid mutations described herein are present in regions outside the CDRs (e.g., in the FRs). More preferably, the amino acid mutations described herein are present in regions outside the heavy chain variable region and / or outside the light chain variable region.

[0155] In some cases, the anti-PD-L1 antibodies of the invention comprise post-translational modifications to the light chain variable region, heavy chain variable region, light chain, or heavy chain. Exemplary post-translational modifications include disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.

[0156] In some embodiments, the substitution is a conservative substitution. A conservative substitution refers to the replacement of an amino acid with another amino acid of the same class, such as the replacement of an acidic amino acid with another acidic amino acid, a basic amino acid with another basic amino acid, or a neutral amino acid with another neutral amino acid. Exemplary substitutions are shown in Table D below.

[0157] [Table 5]

[0158] In certain embodiments, the antibodies provided herein are altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites in an antibody can be advantageously accomplished by altering the amino acid sequence such that one or more glycosylation sites are created or removed.

[0159] For example, one or more amino acid substitutions can be made to remove one or more variable region framework glycosylation sites, thereby removing glycosylation at that site. Such glycosylation can increase the affinity of the antibody for the antigen. See, for example, U.S. Patent Nos. 5,714,350 and 6,350,861. Antibodies with altered glycosylation classes can be made, such as hypofucosylated antibodies with reduced amounts of fucosyl residues or antibodies with increased bisecting GlcNac structures. Such altered glycosylation patterns have shown the ability to enhance ADCC of antibodies. Such glycosylation can be achieved, for example, by expressing the antibody in a host cell with an altered glycosylation system. Cells with altered glycosylation systems have been described in the art and can be used as host cells to express the antibodies of the invention, thereby producing antibodies with altered glycosylation. For example, cell lines Ms704, Ms705, and Ms709 lack the fucosyltransferase gene FUT8 (α(1,6)-fucosyltransferase), and thus antibodies expressed in cell lines Ms704, Ms705, and Ms709 lack fucose in their glycans. Cell lines Ms704, Ms705, and Ms709FUT8- / - were generated using two selective vectors that target the FUT8 gene for disruption in CHO / DG44 cells (see U.S. Patent Application Publication No. 20040110704 and Yamane-Ohnuki et al. (2004) Biotechnol Bioeng 87:614-22). EP 1,176,195 describes cell lines in which the FUT8 gene encoding fucosyltransferase has been functionally disrupted, such that antibodies expressed in the cell line exhibit reduced fucosylation by reducing or eliminating α-1,6 bond-related enzymes. EP 1,176,195 also describes cell lines that have reduced or no enzymatic activity that adds fucose to N-acetylglucosamine attached to the Fc region of antibodies, such as the rat myeloma cell line YB2 / 0 (ATCC CRL 1662).PCT Publication WO03 / 035835 describes a mutant CHO cell line, Lec13 cells, that has a reduced ability to add fucose to Asn(297)-linked glycans, thereby resulting in hypofucosylation of antibodies expressed in the host cells (see also Shields et al. (2002) J. Biol. Chem. 277:26733-26740). Antibodies with modified glycosylation profiles can also be produced in eggs, as described in PCT Publication WO06 / 089231. Alternatively, antibodies with modified glycosylation profiles can be produced in plant cells, such as duckweed. Methods for producing antibodies in plant systems are disclosed in U.S. Patent Application filed August 11, 2006, corresponding to Alston and Bird LLP Attorney Docket No. 040989 / 314911. PCT International WO99 / 54342 describes cell lines engineered to express glycosyltransferases that modify glycoproteins [e.g., β(1,4)-N-acetylglucosaminyltransferase III (GnTIII)] such that antibodies expressed in the engineered cell lines exhibit increased bisecting GlcNac structures, resulting in increased ADCC activity of the antibodies [see also Umana et al. (1999) Nat. Biotech. 17:176-180]. Alternatively, fucosidases can be used to cleave fucosyl residues from antibodies, e.g., α-L-fucosidase removes fucosyl residues from antibodies [Tarentino et al. (1975) Biochem. 14:5516-23].

[0160] In one embodiment of the invention, the antibody or fragment of the invention is glycosylated with engineered yeast N-linked glycans or CHO N-linked glycans.

[0161] Another modification of the antibodies or fragments thereof described herein that is encompassed by the present invention is pegylation. The antibodies can be pegylated, for example, to extend the biological (e.g., serum) half-life of the antibody. To pegylate an antibody, the antibody or fragment thereof is generally reacted with polyethylene glycol (PEG) (e.g., a reactive ester or aldehyde derivative of PEG) under conditions in which one or more PEG groups are attached to the antibody or antibody fragment. Preferably, pegylation is carried out by an acylation reaction or an alkylation reaction using a reactive PEG molecule (or a similar reactive water-soluble polymer). As used herein, the term "polyethylene glycol" is intended to encompass any form of PEG that has been used to derivatize other proteins, such as mono (C1-C10) alkoxy- or aryloxypolyethylene glycol or polyethylene glycol-maleimide. In certain embodiments, the antibody to be pegylated is a non-glycosylated antibody. Methods for the pegylation of proteins are known in the art and are applicable to the antibodies of the present invention, see, for example, EP0154316 and EP0401384.

[0162] In certain embodiments, one or more amino acid modifications can be introduced into the Fc region of the antibodies provided herein to produce Fc region variants that enhance the efficacy of the antibody, for example, in treating cancer or cell proliferative disorders. The anti-PD-L1 antibodies (e.g., humanized or chimeric antibodies) and antigen-binding fragments thereof disclosed herein also include antibodies and fragments with modified (or closed) Fc regions to provide altered effector functions. See, e.g., U.S. Patent No. 5,624,821, WO2003 / 086310, WO2005 / 120571, WO2006 / 0057702. Such modifications can be used to enhance or suppress various responses of the immune system, which can have beneficial effects in diagnosis and therapy. Modifications of the Fc region include amino acid mutations (substitutions, deletions and insertions), glycosylation or deglycosylation, and the addition of multiple Fcs. Modifications to the Fc can also alter the half-life of the antibody in therapeutic antibodies, thereby allowing for less frequent dosing and thus increased convenience and reduced material usage. See Presta (2005) J. Allergy Clin. Immunol. 116:731, pp. 734-735.

[0163] In one embodiment, the number of cysteine ​​residues of an antibody can be altered to modify antibody properties. For example, the hinge region of CH1 is modified to change (e.g., increase or decrease) the number of cysteine ​​residues in the hinge region. This method is further described in U.S. Patent No. 5,677,425. For example, the number of cysteine ​​residues in the hinge region of CH1 can be altered to facilitate assembly of light and heavy chains or to increase or decrease the stability of the antibody.

[0164] In certain embodiments, the antibodies provided herein can be further modified to include other non-proteinaceous moieties that are known in the art and readily available. Suitable moieties for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers), and dextran or poly(n-ethylenemethylpyrrolidone) polyethylene glycol, propylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. The polymer can be of any molecular weight and can be branched or unbranched. The number of polymers attached to the antibody can vary, and when two or more polymers are attached, they can be the same or different molecules. In general, the number and / or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular characteristic or function of the antibody to be improved, whether the antibody derivative will be used in therapy for a defined condition, etc.

[0165] In some embodiments, the invention encompasses fragments of anti-PD-L1 antibodies. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, diabodies, linear antibodies, single-chain antibodies (e.g., scFv), single domain antibodies, and bispecific antibodies formed from antibody fragments.

[0166] For example, the antibody molecule may comprise a heavy chain (HC) variable domain sequence and a light chain (LC) variable domain sequence. In one embodiment, the antibody molecule (herein referred to as an incomplete antibody) comprises or consists of a heavy chain and a light chain. In another example, the antibody molecule comprises two heavy chain variable domain sequences and two light chain variable domain sequences, thereby forming two antigen binding sites. Such Fab, Fab', F(ab')2, Fc, Fd, Fd', Fv, single chain antibodies (e.g., scFv), single domain antibodies, diabodies (Dab) (bivalent and bispecific) and chimeric (e.g., humanized) antibodies can be produced by modifying intact antibodies or can be synthesized de novo using recombinant DNA technology. These functional antibody fragments retain the ability to selectively bind to their corresponding antigen or receptor. The antibodies and antibody fragments may be from any antibody class, including but not limited to IgG, IgA, IgM, IgD, and IgE, and from any antibody subclass (e.g., IgG1, IgG2, IgG3, and IgG4). Preparations of antibody molecules may be monoclonal or polyclonal. The antibody may be human, humanized, chimeric, CDR-grafted, or in vitro produced. The antibody may have a heavy chain constant region selected from, for example, IgG1, IgG2, IgG3, or IgG4. The antibody may also have a light chain selected from, for example, kappa or lambda.

[0167] The antibody of the present invention may also be a single domain antibody. Single domain antibodies may include antibodies whose complementarity determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally lacking light chains, single domain antibodies or engineered antibodies derived from traditional four-chain antibodies. Single domain antibodies may be any antibody of the prior art or any single domain antibody to come. Single domain antibodies may be from any species including, but not limited to, mouse, human, camel, alpaca, fish, shark, goat, rabbit, and cow. According to another aspect of the present invention, the single domain antibody is a naturally occurring single domain antibody, referred to as a heavy chain antibody lacking light chains. Such single domain antibodies are disclosed, for example, in WO94 / 04678. Single domain antibodies or nanobodies may be antibodies produced from camelid species such as camel, alpaca, dromedary, llama, and guanaco. Species other than camelids can naturally produce heavy chain antibodies devoid of light chains, and such single domain antibodies are within the scope of the present invention.

[0168] In some embodiments, the anti-PD-L1 antibodies of the invention are humanized antibodies. Various methods for humanizing antibodies are known to those skilled in the art, as outlined in Almagro and Fransson [Almagro JC and Fransson J (2008) Frontiers in Bioscience 13:1619-1633], the contents of which are incorporated herein by reference in their entirety. Almagro and Fransson distinguish between rational and empirical approaches. Rational approaches are characterized by generating a small number of engineered antibody variants and evaluating their binding or any other characteristic of interest. If a design variant does not yield the expected results, a new round of design and synthesis evaluation is initiated. Rational approaches include CDR grafting, resurfacing, hyperhumanization, and human string content optimization. In contrast, empirical methods are based on the generation of large libraries of humanized variants and the selection of the best clones using enrichment techniques or high-throughput screening. Thus, empirical approaches rely on reliable selection and / or screening systems capable of screening a large number of antibody variants. In vitro display techniques such as phage display and ribosome display meet these requirements and are well known to those skilled in the art. Empirical approaches include FR library construction, guide selection, framework shuffling, and humaneering.

[0169] In some embodiments, the anti-PD-L1 antibody is a human antibody. Human antibodies can be made by a variety of techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr. Opin. Pharmacol 5:368-74(2001) and Lonberg, Curr. Opin. Immunol 20:450-459(2008). For use in producing human monoclonal antibodies, transgenic mice carrying human immunoglobulin genes, for example, can be used rather than the mouse system (see, e.g., Wood et al., International Application WO 91 / 00906; Kucherlapati et al., PCT Publication WO 91 / 10741; Lonberg et al., International Application WO 92 / 03918; Kay et al., International Application 92 / 03917; Lonberg, N. et al., 1994 Nature 368:856-859; Green, LL et al., 1994 Nature Genet. 7:13-21; Morrison, SL et al., 1994 Proc. Natl. Acad. Sci. USA 81:6851-6855; Bruggeman et al., 1993 Yeast Immunol 7:33-40; Tuaillon et al., 1993 PNAS 368:856-859). 90:3720-3724; and Bruggeman et al., 1991 Eur J Immunol 21:1323-1326).

[0170] In some embodiments, the anti-PD-L1 antibodies of the invention are non-human antibodies, such as rodent (mouse or rat) antibodies, goat antibodies, primate (e.g. monkey) antibodies and camelid antibodies. Preferably, the non-human antibodies are rodent (mouse or rat) antibodies. Methods for producing rodent antibodies are known in the art.

[0171] In some embodiments, the antibody of the present invention is a chimeric antibody. Some chimeric antibodies are described, for example, in U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA. 81:6851-6855, 1984. In one embodiment, the chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a non-human primate, such as a mouse, rat, hamster, rabbit, or monkey) and a human constant region. In another embodiment, the chimeric antibody is a "class-switched" antibody whose class or subclass has been changed compared to the class or subclass of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

[0172] In certain embodiments, the chimeric antibody is a humanized antibody. Generally, a non-human antibody is humanized to reduce its immunogenicity in humans while retaining the specificity and affinity of its parent non-human antibody. Generally, a humanized antibody comprises one or more variable domains, e.g., the CDRs (or portions thereof) are derived from a non-human antibody and the FRs (or portions thereof) are derived from a human antibody sequence. Optionally, the humanized antibody further comprises at least a portion of a human constant region. In some embodiments, some FR residues of the humanized antibody are replaced by the corresponding residues of a non-human antibody (e.g., the antibody from which the CDR residues are derived), e.g., to restore or improve the specificity or affinity of the antibody.

[0173] Antibodies of the invention can be isolated by screening combinatorial libraries for antibodies with the desired activity. For example, various methods are known in the art for generating phage display libraries and screening these libraries for antibodies with the desired binding characteristics. These methods are described, for example, in Hoogenboom et al., Methods in Molecular Biology 178:1-37 (O'Brien et al., eds., Human Press, Totowa, NJ, 2001), and further described, for example, in McCafferty et al., Nature 348:552-554; Clackso et al., Nature 352:624-628 (1991); Marks et al., J.Mol.Biol. 222:581-597(1992); Marks and Bradbury, Methods in Molecular Biology 248:161-175 (Lo, eds., Human Press, Totowa, NJ, 2003); Sidhu et al., J.Mol.Biol. 338(2):299-310(2004); Lee et al., J. Mol. Biol 340(5):1073-1093(2004); Fellouse, Proc. Natl. Acad. Sci. USA 101 (34):12467-12472(2004); and Lee et al., J. Immunol. Methods 284(1-2):119-132(2004).

[0174] In one embodiment, the antibody molecule is a monospecific antibody molecule, which binds to a single epitope, e.g., a monospecific antibody molecule comprises multiple immunoglobulin variable domain sequences, each of which binds to the same epitope.

[0175] In one embodiment, the antibody molecule is a multispecific antibody molecule, e.g., the antibody molecule comprises a plurality of immunoglobulin variable domain sequences, a first immunoglobulin variable domain sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope. In one embodiment, the first and second epitopes are present on the same antigen (e.g., the same protein or the same subunit of a multimeric protein). In one embodiment, the first epitope and the second epitope overlap. In one embodiment, the first epitope and the second epitope do not overlap. In one embodiment, the first epitope and the second epitope are present on different antigens (e.g., different proteins or different subunits of a multimeric protein). In one embodiment, the multispecific antibody molecule comprises a third, fourth or fifth immunoglobulin variable domain. In one embodiment the multispecific antibody molecule is a bispecific antibody molecule or a trispecific antibody molecule or a tetraspecific antibody molecule.

[0176] In one embodiment, the multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody is specific for at most two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence having binding specificity for a first epitope and a second immunoglobulin variable domain sequence having binding specificity for a second epitope. In one embodiment, the first epitope and the second epitope are present on the same antigen (e.g., the same protein or the same subunit of a multimeric protein). In one embodiment, the first epitope and the second epitope overlap. In one embodiment, the first epitope and the second epitope do not overlap. In one embodiment, the first epitope and the second epitope are present on different antigens (e.g., different proteins or different subunits of a multimeric protein). In one embodiment, a bispecific antibody molecule comprises heavy and light chain variable domain sequences that have binding specificity for a first epitope and heavy and light chain variable domain sequences that have binding specificity for a second epitope. In one embodiment, a bispecific antibody molecule comprises an incomplete antibody that has binding specificity for a first epitope and an incomplete antibody that has binding specificity for a second epitope. In one embodiment, a bispecific antibody molecule comprises an incomplete antibody, or fragment thereof, that has binding specificity for a first epitope and an incomplete antibody, or fragment thereof, that has binding specificity for a second epitope. In one embodiment, a bispecific antibody molecule comprises an scFv, or fragment thereof, that has binding specificity for a first epitope and an scFv, or fragment thereof, that has binding specificity for a second epitope. In one embodiment, the first epitope is on PD-L1 and the second epitope is on LAG-3, OX40, TIM-3, CEACAM (e.g., CEACAM-1 and / or CEACAM-5), or PD-L2.

[0177] In some embodiments, the present invention further provides an anti-PD-L1 monoclonal antibody conjugated to another agent, e.g., a therapeutic moiety or marker, e.g., a cytotoxic agent or an immunomodulatory agent (an "immunoconjugate"). A cytotoxic agent includes any agent that is detrimental to cells. Examples of cytotoxic agents (e.g., chemotherapeutic agents) suitable for forming an immunoconjugate are known in the art, see, e.g., WO2015 / 153513 or WO2015 / 138920. For example, cytotoxic agents include, but are not limited to, radioisotopes, e.g., iodine ( 131 I or 125 I), yttrium ( 90 Y), lutetium ( 177 Lu), Actinium ( 225 Ac), praseodymium, astatine ( 211 At), Rhenium ( 186 Re), Bismuth ( 212 Bi or 213 Bi), Indium ( 111 In), Technetium ( 99m Tc), phosphorus ( 32 P), Rhodium ( 188 Rh), Sulfur ( 35 S), carbon ( 14 C), tritium ( 3 H), Chromium ( 51 Cr), Chlorine ( 36 Cl), Cobalt ( 57 Co or 58 Co), Iron ( 59 Fe), Selenium ( 75 Se), or gallium ( 67Examples of cytotoxic agents further include chemotherapeutic agents or other therapeutic substances such as paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunomycin, dihydroxyanthraquinone diketones, mitoxantrone, mithramycin, actinomycin D, 1-dihydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or congeners of all of the above therapeutic agents. Cytotoxic agents further include, for example, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil, and dacarbazine), alkylating agents (e.g., mechlorethamine, thioephaloramucil, melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiammineplatinum(II) (DDP) cisplatin), anthramycins (e.g., daunorubicin (formerly known as daunomycin) and doxorubicin), antibiotics (e.g., actinomycin D (formerly known as actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and antimitotic agents (e.g., vincristine and vinblastine).

[0178] Substances that can be conjugated / coupled to anti-PD-L1 antibodies can be found, for example, in WO2010 / 077634 or US60 / 696426 or WO2016 / 007235 or WO2016 / 061142.

[0179] Nucleic acids of the invention and host cells comprising same In one embodiment, the invention provides a nucleic acid encoding an anti-PD-L1 antibody or fragment thereof as described above, which may encode an amino acid sequence comprising the light chain variable region and / or the heavy chain variable region of the antibody, or an amino acid sequence comprising the light chain and / or the heavy chain of the antibody.

[0180] For example, exemplary nucleic acids of the present invention include nucleic acids encoding an amino acid sequence selected from any one of SEQ ID NOs: 26-51, or nucleic acids encoding an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to an amino acid sequence selected from any one of SEQ ID NOs: 26-51.

[0181] The present invention further provides a nucleic acid that hybridizes under stringent conditions to the following nucleic acids, or variants of the following nucleic acids having one or more substitutions (e.g., conservative substitutions), deletions or insertions: a nucleic acid encoding an amino acid sequence selected from any one of SEQ ID NOs: 26-51; or a nucleic acid encoding an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to an amino acid sequence selected from any one of SEQ ID NOs: 26-51.

[0182] In one embodiment, one or more vectors containing the nucleic acid are provided. In one embodiment, the vector is an expression vector, such as a eukaryotic expression vector. Vectors include, but are not limited to, viruses, plasmids, cosmids, lambda phage, or yeast artificial chromosomes (YACs). Many vector systems are available. For example, one class of vectors uses DNA elements derived from animal viruses, such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retrovirus (Rous sarcoma virus or MMTV or MOMLV), and SV40 virus. Another class of vectors uses RNA elements derived from RNA viruses, such as Semliki Forest virus, Eastern equine encephalitis virus, and flaviviruses. In a preferred embodiment, the expression vector of the invention is a pTT5 expression vector.

[0183] In addition, cells in which the DNA has been stably integrated into their chromosomes can be selected by introducing one or more markers that allow for the selection of transfected host cells. These markers can provide, for example, prototrophy, biocide (e.g., antibiotic) resistance, or heavy metal (e.g., copper) resistance for auxotrophic hosts. The selectable marker gene can be directly linked to the DNA sequence so that it is expressed or introduced by cotransformation into the same cell. Additional elements may also be required for optimal synthesis of mRNA. These elements may include splicing signals, transcription promoters, enhancers, and termination signals.

[0184] Once an expression vector or DNA sequence is produced for expression, the expression vector can be transfected or introduced into a suitable host cell.Various techniques can be used for this purpose, such as protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, microprojectile bombardment, lipid-based transfection, or other conventional techniques.In the case of protoplast fusion, the cells are incubated in culture medium and screened for appropriate activity.The methods and conditions for incubating the resulting transfected cells and for recovering the resulting antibody molecules are known to those skilled in the art and can be modified or optimized according to the specific expression vector and the specific mammalian host cell used based on the present specification and the methods known in the art.

[0185] In one embodiment, a host cell is provided that contains a nucleic acid encoding an antibody molecule as described herein or a vector as described herein. Suitable host cells for cloning or expressing an antibody encoding nucleic acid or vector include prokaryotic or eukaryotic cells as described herein. Antibodies can be produced, for example, in bacteria, particularly when glycosylation and Fc effector functions are not required. Expression of antibody fragments and polypeptides in bacteria is described, for example, in U.S. Pat. Nos. 5,648,237, 5,789,199 and 5,840,523, and also in Charlton, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes the expression of antibody fragments in E. coli. After expression, the antibody can be isolated from the bacterial paste in a soluble fraction and can be further purified. In one embodiment, the host cell is E. coli.

[0186] In one embodiment, the host cell is eukaryotic. In another embodiment, the host cell is selected from the group consisting of yeast, mammalian cells (e.g., human cells), insect cells, plant cells, or other cells suitable for producing antibodies or antigen-binding fragments thereof. For example, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeasts whose glycosylation pathways have been "humanized" to result in the production of antibodies with partial or fully human glycosylation patterns (see Gerngross, Nat. Biotech. 22: 1409-1414 (2004), and Nat. Biotech. 24:210-215 (2006)). Suitable host cells for the expression of glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates).

[0187] Vertebrate cells may also be used as hosts. For example, mammalian cell lines engineered to be suitable for suspension growth can be used. Other examples of useful mammalian host cell lines include the SV40 transformed monkey kidney CV1 line (COS-7), human embryonic kidney lines (e.g., 293HEK or 293 cells as described in Graham et al., J. Gen Virol. 36: 59 (1977)), and the like. Other useful mammalian host cell lines include the DHFR - These include Chinese hamster ovary (CHO) cells, including CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77: 216 (1980)), as well as myeloma cell lines such as Y0, NS0, and Sp2 / 0.

[0188] A review of certain mammalian host cell lines suitable for antibody production can be found, for example, in Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003). Other useful host cells include, but are not limited to, Vero cells, Hela cells, COS cells, CHO cells, HEK293 cells, BHK cells, MDCKII cells, oocytes from the PerC6 cell line (e.g., PERC6 cells from Crucell), and cells from transgenic animals such as mammary epithelial cells. Suitable insect cells include, but are not limited to, Sf9 cells.

[0189] Methods for Producing Antibodies and Antigen-Binding Fragments Thereof The anti-PD-L1 antibodies disclosed herein can be recombinantly produced. There are several methods known in the art for the production of recombinant antibodies. One example of a method for the recombinant production of antibodies is disclosed in U.S. Patent No. 4,816,567.

[0190] In one embodiment, a method for producing an anti-PD-L1 antibody is provided, comprising incubating a host cell containing nucleic acid encoding the antibody under conditions suitable for expression of the antibody, as set forth above, and optionally recovering the antibody from the host cell (or host cell culture). For recombinant production of an anti-PD-L1 antibody, nucleic acid encoding the antibody (such as those described above) is isolated and inserted into one or more vectors for further cloning and / or expression in a host cell. The nucleic acid is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of specifically binding to genes encoding the heavy and light chains of the antibody).

[0191] In one embodiment, the host cell comprises a vector comprising a nucleic acid encoding the amino acid sequence of the antibody VL and a nucleic acid encoding the amino acid sequence of the antibody VH. In one embodiment, the host cell comprises a first vector comprising a nucleic acid encoding the amino acid sequence of the antibody VL and a second vector comprising a nucleic acid encoding the amino acid sequence of the antibody VH.

[0192] Assay The anti-PD-L1 antibodies provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activity by various assays known in the art. In one embodiment, the antigen-binding activity of the antibodies of the invention is tested by known methods, such as, for example, ELISA, Western blotting, flow cytometry, and magnetic beads coated with antibody molecules. PD-L1 binding can be determined by methods known in the art, and exemplary methods are disclosed herein. In some embodiments, biological optical interferometry (e.g., Fortebio affinity assay) or MSD assay or flow cytometry is used.

[0193] In other aspects, competitive binding assays can be used to identify antibodies that compete with the anti-PD-L1 antibodies disclosed herein for binding to D-L1. In some embodiments, such competing antibodies bind to the same epitope (e.g., a linear or conformational epitope) as any of the anti-PD-L1 antibodies disclosed herein. Detailed exemplary methods for localizing antibody binding epitopes are described in Morris (1996) "Epitope Mapping Protocols", Methods in Molecular Biology Vol. 66 (Humana Press, Totowa, NJ).

[0194] The invention further provides assays for identifying anti-PD-L1 antibodies having one or more of the above properties, and further provides antibodies having such biological activity in vivo and / or in vitro.

[0195] In some embodiments, the antibodies of the invention are tested for one or more of the above properties.

[0196] Cells for use in any of the above in vitro assays include cells or cell lines that naturally express PD-L1 or that have been engineered to express PD-L1.

[0197] It will be appreciated that any of the above assays may be performed by using an immunoconjugate of the invention in place of, or in addition to, an anti-PD-L1 antibody.

[0198] It will be appreciated that any of the above assays may be performed using anti-PD-L1 antibodies and other therapeutic agents.

[0199] Pharmaceutical Compositions and Formulations The present invention further provides compositions (including pharmaceutical compositions or pharmaceutical formulations) comprising an anti-PD-L1 antibody, or a fragment of that antibody, or an immunoconjugate thereof, as well as compositions comprising nucleic acids encoding anti-PD-L1 antibodies, or fragments thereof. In certain embodiments, the compositions comprise one or more antibodies that bind to PD-L1 or a fragment of that antibody, or an immunoconjugate thereof, or one or more nucleic acids encoding one or more antibodies that bind to PD-L1 or a fragment thereof. Such compositions may further contain suitable pharmaceutical auxiliary materials, such as pharmaceutical carriers, excipients, including buffers, that are known in the art.

[0200] The pharmaceutical carrier suitable for use in the present invention can be sterile liquid such as water and oil, including petroleum or oil of animal, vegetable or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, etc. Water is the preferred carrier when the pharmaceutical composition is administered intravenously. Saline and aqueous dextrose and glycerol solutions can also be used as liquid carriers, particularly for use in injectable solutions.

[0201] Suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, etc. For the use of excipients, see "Handbook of Pharmaceutical Excipients", 5th Edition, RC Rowe, PJ Seskey and SC Owen, Pharmaceutical Press, London, Chicago.

[0202] The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering.

[0203] These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained release formulations, etc. Oral formulations can contain standard carriers and / or excipients such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, and saccharin.

[0204] Pharmaceutical formulations comprising the anti-PD-L1 antibodies described herein, preferably in the form of a lyophilized formulation or aqueous solution, may be made by mixing anti-PD-L1 antibodies of the desired purity with one or more optional pharmaceutical auxiliary ingredients [Remington's Pharmaceutical Sciences, 16th Edition, Edited by Osol, A. (1980)].

[0205] Exemplary lyophilized antibody formulations are described in U.S. Patent No. 6,267,958. Aqueous antibody formulations include those described in U.S. Patent No. 6,171,586 and WO2006 / 044908, the latter formulations comprising a histidine-acetate buffer.

[0206] The pharmaceutical compositions or formulations of the invention may also contain more than one active ingredient as required by the particular indication being treated, preferably active ingredients with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide other anti-cancer active ingredients, such as chemotherapeutic agents and / or cytotoxic agents. The active ingredients are suitably combined in amounts effective for the intended purpose. The active ingredient may be any agent known in the art that can be combined with an anti-PD-L1 antibody, including chemotherapeutic agents, other antibodies, and other therapeutic agents. Examples of active ingredients can be found, for example, in WO2010 / 077634, WO2016 / 061142, US61 / 264061, US60 / 696426, WO2016 / 007235, and the like.

[0207] In some embodiments, the active ingredient is an anti-LAG-3 antibody, eg, an anti-LAG-3 antibody that binds to a human antigen, preferably the anti-LAG-3 antibody is humanized.

[0208] Sustained-release preparations can be made. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.

[0209] Use of antibodies In one aspect, the invention relates to a method for modulating an immune response in a subject, the method comprising administering to the subject an effective amount of an antibody molecule (e.g., an anti-PD-L1 antibody) or pharmaceutical composition or immunoconjugate disclosed herein, thereby modulating the immune response in the subject. In one embodiment, the antibody molecule (e.g., a therapeutically effective amount of an anti-PD-L1 antibody molecule) or pharmaceutical composition or immunoconjugate disclosed herein restores, enhances, stimulates or augments the immune response in the subject.

[0210] In another aspect, the present invention relates to a method for preventing or treating a tumor (e.g., cancer) in a subject, the method comprising administering to the subject an effective amount of an antibody molecule (e.g., an anti-PD-L1 antibody) or pharmaceutical composition or immunoconjugate disclosed herein. In some embodiments, the tumor is a tumor immune escape. Preferably, the tumor is a gastrointestinal tumor (e.g., cancer), for example, colon cancer.

[0211] In another aspect, the invention relates to a method for preventing or treating an infectious disease in a subject, the method comprising administering to the subject an effective amount of an antibody molecule (e.g. an anti-PD-L1 antibody) or pharmaceutical composition or immunoconjugate disclosed herein. In one embodiment, the infectious disease is a chronic infectious disease.

[0212] In another aspect, the invention relates to a method for inducing antibody-dependent cell-mediated cytotoxicity in a subject, the method comprising administering to the subject an effective amount of an antibody molecule (e.g. an anti-PD-L1 antibody) or pharmaceutical composition or immunoconjugate disclosed herein.

[0213] The subject may be a mammal, e.g., a primate, preferably a higher primate, e.g., a human (e.g., a patient having or at risk of having a disease described herein). In one embodiment, the subject is in need of an enhanced immune response. In some embodiments, the anti-PD-L1 antibody molecules described herein promote T cell proliferation. In some embodiments, the anti-PD-L1 antibody molecules described herein restore, promote, or stimulate an antigen-specific T cell response in the subject, e.g., interleukin-2 (IL-2) or interferon-γ (IFN-γ) production in the antigen-specific T cell response. In some embodiments, the immune response is an anti-tumor response. In one embodiment, the subject has or is at risk of having a disease described herein (e.g., a tumor or infectious disease described herein). In certain embodiments, the subject is immunocompromised or at risk of being immunocompromised. For example, the subject is undergoing or has undergone chemotherapy and / or radiation therapy. Alternatively, or in combination, the subject is immunocompromised due to an infection or is at risk of being immunocompromised due to an infection.

[0214] In some embodiments, tumors, eg, cancers, described herein include, but are not limited to, solid tumors, hematological cancers, soft tissue tumors, and metastatic lesions.

[0215] Examples of solid tumors include malignant tumors of various organ systems, such as sarcomas and carcinomas (including adenocarcinomas and squamous cell carcinomas), such as carcinomas affecting the liver, lung, breast, lymph, gastrointestinal tract (e.g., colon), genitourinary tract (e.g., kidney and bladder epithelial cells), prostate, and pharynx. Adenocarcinomas include malignant tumors such as most colon cancers, rectal cancer, renal cell carcinoma, liver cancer, non-small cell carcinoma of the lung, small intestine cancer, and esophageal cancer. Squamous cell carcinomas include malignant tumors such as carcinomas of the lung, esophagus, skin, head and neck region, oral cavity, anus, and cervix. In one embodiment, the cancer is melanoma, e.g., advanced melanoma. In one embodiment, the cancer is a gastrointestinal cancer, such as colon cancer. Metastatic lesions of the above carcinomas can also be treated or prevented by using the methods and compositions of the present invention.

[0216] Non-limiting examples of preferred cancers to be treated include lymphoma (e.g., diffuse large B-cell lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma), breast cancer (e.g., metastatic breast cancer), lung cancer (e.g., non-small cell lung cancer (NSCLC), e.g., stage IV or recurrent non-small cell lung cancer, NSCLC adenocarcinoma, or NSCLC squamous cell carcinoma), myeloma (e.g., multiple myeloma), leukemia (e.g., chronic myelogenous leukemia), skin cancer (e.g., melanoma (e.g., stage III or IV melanoma) or Merkel cell carcinoma), head and neck cancer (e.g., head and neck squamous cell carcinoma (HNSCC)), myelodysplastic syndrome, bladder cancer (e.g., transitional cell carcinoma), kidney cancer (e.g., renal cell carcinoma, e.g., clear cell renal cell carcinoma, e.g., advanced or metastatic clear cell renal cell carcinoma), and colon cancer. In addition, refractory or recurrent malignancies may be treated by using the antibody molecules described herein.

[0217] Examples of other cancers that can be treated include bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, gastroesophageal cancer, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Merkel cell carcinoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, chronic or acute leukemia (acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic ... cancer, including myeloid leukemia, blastic leukemia, and chronic lymphocytic leukemia, childhood solid tumors, lymphocytic lymphoma, bladder cancer, multiple myeloma, myelodysplastic syndrome, kidney or ureter cancer, renal pelvis cancer, central nervous system (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, axial tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, and environmentally induced cancers (including asbestos induced cancers, e.g., mesothelioma), and combinations thereof.

[0218] Treatment of metastatic cancers, such as metastatic cancers that express PD-L1 (Iwai et al., (2005) Int. Immunol. 17:133-144), may be carried out by using the antibody molecules described herein.

[0219] Tumor immune escape is also treatable by using the antibody molecules described herein.

[0220] In one embodiment, the tumor is a cancer that expresses high levels of PD-L1.

[0221] In some embodiments, the cancer described herein is colon cancer and metastatic cancers thereof.

[0222] In some embodiments, the infection is acute or chronic. In some embodiments, the chronic infection is a persistent infection, a latent infection, or a delayed infection. In some embodiments, the chronic infection is caused by a pathogen selected from the group consisting of bacteria, viruses, fungi, and protozoa.

[0223] In some embodiments, the pathogen is a bacterium. In one embodiment, the bacterium is a Mycobacterium species ( Mycobacterium spp.), Salmonella spp. Salmonella spp.), Listeria spp. Listeria spp.), Streptococcus sp. Streptococcus spp.), Haemophilus spp. Haemophilus spp.), Neisseria spp. Neisseria spp.), Klebsiella spp. Klebsiella spp.), Borrelia spp. Borrelia spp.), Bacteroides fragilis ( Bacterioides Fragile ), Treponema species ( Treponema spp.), and Helicobacter pylori ( Helicobacter pylori ).

[0224] In some embodiments, the pathogen is a virus. In one embodiment, the virus is an infectious virus, such as, for example, selected from the group consisting of Hepatitis B or C virus (HBV or HCV), Herpes Simplex Virus I or II, Human Immunodeficiency Virus I or II, Cytomegavirus, Epstein-Barr Virus (EBV), Human Papillomavirus, Human T-Lymphotropic Leukemia Virus I or II, and Varicella-Zoster Virus.

[0225] In some embodiments, the pathogen is a fungus. In one embodiment, the fungal-induced disorder is selected from the group consisting of aspergilosis, blastomycosis, candidiasis albicans, coccidioiodmycosis immitis, histoplasmosis, paracoccidioidomycosis, and microsporidiosis.

[0226] In some embodiments, the pathogen is a protozoan, such as a parasite. In one embodiment, the disorder caused by a protozoan is selected from the group consisting of leishmaniasis, plasmodiosis (i.e., malaria), cryptosporidiosis, toxoplasmosis, trypanosomiasis, and helminth infections (including diseases caused by trematodes (e.g., schistosomiasis), cestodes (e.g., echinococcosis), and nematodes (e.g., trichinosis), ascariasis, filariasis, and strongyloidiasis).

[0227] In another embodiment, the infection is a hepatitis infection, such as a hepatitis B or hepatitis C infection. The anti-PD-L1 antibody molecule may be advantageously combined with a conventional treatment for hepatitis B or hepatitis C infection. In a particular embodiment, the anti-PD-L1 antibody molecule is administered in combination with a hepatitis B antigen (e.g. Engerix B) or vaccine, optionally in combination with an aluminium-containing adjuvant.

[0228] In another embodiment, the infectious disease is influenza. In a specific embodiment, the anti-PD-L1 antibody molecule is administered in combination with an influenza antigen or vaccine.

[0229] Further diseases suitable for prevention or treatment using the anti-PD-L1 antibodies, or fragments thereof, of the invention can be found in WO2010 / 077634, WO2016 / 061142, US60 / 696426, WO2016 / 007235 or US61 / 264061.

[0230] In another aspect, the invention provides the use of an anti-PD-L1 antibody, or a fragment thereof, or an immunoconjugate thereof in the manufacture or preparation of a medicament for the prevention or treatment of any of the above related diseases or conditions.

[0231] In some embodiments, the antibodies or antibody fragments or immunoconjugates of the invention delay the onset of pathologies and / or symptoms associated with those pathologies.

[0232] Combination therapy In some embodiments, the prophylactic or therapeutic methods described herein further comprise administering to a subject or individual the antibody molecule (e.g., an anti-PD-L1 antibody or fragment thereof) or pharmaceutical composition or immunoconjugate disclosed herein in combination with one or more other therapies, e.g., therapeutic methods and / or other therapeutic agents.

[0233] In some embodiments, the treatment includes surgery (e.g., tumor resection), radiation therapy (e.g., external beam radiation therapy, including three-dimensional conformal radiation therapy, where the radiation field is designed), partial radiation (e.g., radiation directed to a preselected target or organ), focused radiation, etc. Focused radiation can be selected from the group consisting of stereotactic radiosurgery, stereotactic fractionated radiosurgery, and intensity-modulated radiation therapy. Focused radiation can comprise a radiation source selected from the group consisting of particle beam (protons), cobalt-60 (photons), and linear accelerator (X-rays), as described, for example, in WO2012 / 177624.

[0234] Radiation therapy can be performed by one or a combination of methods, including, but not limited to, external beam radiation therapy, internal radiotherapy, interstitial irradiation, stereotactic radiosurgery, total body radiation therapy, radiotherapy, and permanent or temporary interstitial brachytherapy. The term "brachytherapy" refers to radiation therapy delivered by spatially confined radioactive material inserted into the body at or near the site of a tumor or other proliferative tissue disease. This term is intended to include, but is not limited to, exposure to radioisotopes (e.g., At-211, I-131, I-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32, and radioisotopes of Lu). Suitable sources include solid and liquid. As non-limiting examples, the source can be a radionuclide such as I-125, I-131, Yb-169, and Ir-192 as a solid source, I-125 as a solid source, or other radionuclides that emit photons, beta particles, gamma rays, or other therapeutic rays. The radioactive material can also be any radionuclide solution, for example, a fluid made from an I-125 or I-131 solution, or a radioactive fluid can be produced by using a slurry of a suitable fluid containing small particles of a solid radionuclide (e.g., Au-198 and Y-90). In addition, the radionuclide can be encapsulated in a gel or radioactive microspheres.

[0235] In some embodiments, the therapeutic agent is selected from the group consisting of chemotherapeutic agents, cytotoxic agents, vaccines, other antibodies, anti-infective active agents, and immunomodulatory agents (e.g., costimulatory molecule activators or immune checkpoint molecule inhibitors).

[0236] Exemplary cytotoxic agents include anti-microtubule agents, topoisomerase inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, anthracyclines, vinca alkaloids, intercalating agents, active agents that can interfere with signal transduction pathways, potent apoptotic agents, proteasome inhibitors, and irradiation (e.g., partial or total body irradiation (e.g., gamma rays)).

[0237] Other exemplary antibodies include, but are not limited to, immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-TIM-3, anti-CEACAM, or anti-LAG-3), antibodies that stimulate immune cells (e.g., agonistic GITR antibodies or CD137 antibodies), anti-cancer antibodies (e.g., rituximab (Rituxan® or MabThera®), trastuzumab (Herceptin®), tositumomab (Bexar®), ibritumomab (Zevalin®), alemtuzumab (Campus®), epratuzumab (Linphoside®), bevacizumab (Avastin®), erlotinib (Tarceva®), cetuximab (Erbitux®), and the like.

[0238] Exemplary chemotherapeutic agents include, but are not limited to, anastrozole (Arimitex®), bicalutamide (Casodex®), bleomycin sulfate (Velenoxan®), busulfan (Myleran®), busulfan injection (Busulfex®), capecitabine (Xeloda®), N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin (Parapalatin®), carmustine (BiCNU®), ), chlorambucil (Leukeran®), cisplatin (Platinol®), cladribine (Leustatin®), cyclophosphamide (Cytoxan® or Neosar®), cytosine arabinoside, cytosine arabinoside (Cytosar-U®), DepoCyt®, dacarbazine (DTIC-Dome®), dactinomycin (Actinomycin D and Cosmegan), daunomycin hydrochloride (Cerbidine®), daunomycin citrate Injectable medicament (Daunoxom®), dexamethasone, docetaxel (Taxotere®), doxorubicin hydrochloride (Adriamycin® and Rubex®), etoposide (Vepesid®), fludarabine phosphate (Fludara®), 5-fluorouracil (Adolcil® and Efudex®), flutamide (Eurexin®), tezacitibine, gemcitabine (difluorodeoxycytidine), hydroxyurea (Hydrea®), idarubicin ( Idamycin (registered trademark), ifosfamide (IFEX (registered trademark), irinotecan (Camptosar (registered trademark), L-asparaginase (ELSPAR (registered trademark), calcium folinate, melphalan (Alcran (registered trademark), 6-mercaptopurine (Purintor (registered trademark), methotrexate (Forex (registered trademark), mitoxantrone, gemtuzumab ozogamicin (Mylotarg), paclitaxel (Taxol (registered trademark), Phoenix (Yttrium 90 / MX-DTPA), pentostatin,These include the combination of polipheprosan 20 and carmustine implant (Gliadel®), tamoxifen citrate (Nolvadex®), teniposide (Bumon®), 6-thioguanine, thiotepa, tirapazamine (Tirazoline®), topotecan hydrochloride for injection (Hycamtin®), vinblastine (Velban®), vincristine (Oncovin®), vinorelbine, ibrutinib, Zydelig (idelalisib), and brentuximab vedotin.

[0239] Exemplary vaccines include, but are not limited to, cancer vaccines. Vaccines can be DNA-based vaccines, RNA-based vaccines, or viral transduction-based vaccines. Cancer vaccines can be preventive or therapeutic. In some embodiments, cancer vaccines are peptide cancer vaccines, which in some embodiments are personalized peptide vaccines. In some embodiments, peptide cancer vaccines are multivalent long peptides, multiple peptides, peptide mixtures, hybrid peptides, or peptide-pulsed dendritic cell vaccines (see, for example, Yamada et al., Cancer Sci, 104:14-21, 2013).

[0240] Exemplary active anti-infective agents include, but are not limited to, antiviral, antifungal, antiprotozoal and antibacterial agents, such as nucleoside analogs (zidovudine (AST), ganciclovir, foscarnet, or cidovir), as described above.

[0241] Immunomodulatory agents include immune checkpoint molecule inhibitors and costimulatory molecule activators.

[0242] In some embodiments, the immune checkpoint molecule inhibitor is an inhibitor of PD-1, PD-L2, CTLA-4, TIM-3, LAG-3, CEACAM (e.g., CEACAM-1, -3, and / or -5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and / or TGFRβ. Inhibition of the molecule can occur at the DNA, RNA, or protein level. In some embodiments, inhibitory nucleic acids (e.g., dsRNA, siRNA, or shRNA) can be used to inhibit expression of immune checkpoint molecules. In other embodiments, the immune checkpoint molecule inhibitor is a polypeptide that binds to an immune checkpoint molecule, such as a soluble ligand (e.g., PD-1-Ig or CTLA-4Ig), or an antibody or antigen-binding fragment thereof, e.g., an antibody or fragment thereof that binds to PD-1, PD-L2, CEACAM (e.g., CEACAM-1, -3, and / or -5), CTLA-4, TIM-3, LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and / or TGFRβ, or a combination thereof. In other embodiments, the immunomodulatory agent is an inhibitor of CEACAM (e.g., CEACAM-1, -3, and / or -5) (e.g., human CEACAM (e.g., CEACAM-1, -3, and / or -5)). In other embodiments, the immunomodulatory agent is an inhibitor of LAG-3 (e.g., human LAG-3). In one embodiment, the inhibitor of LAG-3 is an antibody molecule against LAG-3, e.g., an anti-LAG-3 antibody that binds to a human, preferably the anti-LAG-3 antibody is humanized. In another embodiment, the immunomodulatory agent is an inhibitor of TIM-3 (e.g., human TIM-3). In one embodiment, the inhibitor of TIM-3 is an antibody molecule against TIM-3.

[0243] In some embodiments, the immunomodulatory agent is a costimulatory molecule activator or agonist. In one embodiment, the costimulatory molecule agonist is an agonist (e.g., an agonist antibody or antigen-binding fragment thereof, or a soluble fusion) of a molecule selected from the group consisting of OX40, CD2, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, or CD83 ligand. In another embodiment, the immunomodulatory agent is a GITR agonist. In one embodiment, the GITR agonist is an antibody molecule against GITR. In another embodiment, the immunomodulatory agent is an OX40 agonist. In one embodiment, the OX40 agonist is an antibody molecule against OX40.

[0244] In some further embodiments, the anti-PD-L1 antibodies or fragments thereof may also be used in combination with a tyrosine kinase inhibitor (e.g., a receptor tyrosine kinase (RTK) inhibitor). Exemplary tyrosine kinase inhibitors include, but are not limited to, epidermal growth factor (EGF) pathway inhibitors (e.g., epidermal growth factor receptor (EGFR) inhibitors), vascular endothelial growth factor (VEGF) pathway inhibitors (e.g., vascular endothelial growth factor receptor (VEGFR) inhibitors, e.g., VEGFR-1 inhibitors, VEGFR-2 inhibitors, and VEGFR-3 inhibitors), platelet-derived growth factor (PDGF) pathway inhibitors (e.g., platelet-derived growth factor receptor (PDGFR) inhibitors, e.g., PDGFR-β inhibitors), RAF-1 inhibitors, KIT inhibitors, and RET inhibitors.

[0245] In some embodiments, the anti-PD-L1 antibodies or fragments thereof of the invention may also be used in combination with inhibitors such as PI3K inhibitors, mTOR inhibitors, BRAF inhibitors, MEK inhibitors, and / or JAK2 inhibitors.

[0246] In some embodiments of any of the methods of the invention, administration of an anti-PD-L1 antibody or fragment thereof of the invention is combined with administration of an antigen. The antigen can be, for example, a tumor antigen, a viral antigen, a bacterial antigen, or an antigen from a pathogen. In some embodiments, the tumor antigen comprises a protein. In some embodiments, the tumor antigen comprises a nucleic acid. In some embodiments, the tumor antigen is a tumor cell.

[0247] In some embodiments, the anti-PD-L1 antibodies, or fragments thereof, of the invention may be administered in combination with a therapy comprising adoptive cell transfer of T cells (e.g. cytotoxic T lymphocytes or CTLs) expressing a chimeric antigen receptor (CAR).

[0248] In some embodiments, the anti-PD-L1 antibodies, or fragments thereof, of the invention may be administered in combination with an anti-tumor agent.

[0249] In some embodiments, the anti-PD-L1 antibodies or fragments thereof of the present invention can be administered in combination with an oncolytic virus. In some embodiments, the oncolytic virus can selectively amplify in cancer cells and induce cancer cell death or slow the growth of cancer cells. In some cases, the oncolytic virus has no or minimal effect on non-cancer cells. Oncolytic viruses include, but are not limited to, oncolytic adenovirus, oncolytic herpes simplex virus, oncolytic retrovirus, oncolytic parvovirus, oncolytic vaccinia virus, oncolytic Sindbis virus, oncolytic influenza virus, or oncolytic RNA virus (e.g., oncolytic reovirus, oncolytic Newcastle disease virus (NDV), oncolytic measles virus, or oncolytic vesicular stomatitis virus (VSV)). In some embodiments, the oncolytic virus is a virus described in US2010 / 0178684A1, such as a recombinant oncolytic virus.

[0250] In some embodiments, the anti-PD-L1 antibodies, or fragments thereof, of the invention may be administered in combination with cytokines.

[0251] In some embodiments, the antibodies or fragments thereof of the present invention are used in a variety of therapeutic applications, including but not limited to: (i) radiotherapy (e.g., radiotherapy, X-ray therapy, and irradiation) or electromagnetic radiation to kill cancer cells and reduce tumors (wherein radiotherapy can be performed by external beam radiation therapy (EBRT) or internal brachytherapy); (ii) chemotherapy, or application of cytotoxic drugs, which generally affect rapidly dividing cells; (iii) targeted therapies or drugs that specifically affect the deregulation of proteins in cancer cells (e.g., tyrosine kinase inhibitors such as imatinib and gefitinib; monoclonal antibodies; photodynamic therapy; and (iv) targeted therapy. (iv) immunotherapy, or enhancing the host's immune response (e.g., vaccines); (v) hormonal therapy, or hormone blockade (e.g., if the tumor is hormone sensitive); (vi) angiogenesis inhibitors, or therapies that block angiogenesis and growth; and (vii) palliative care, or therapies related to improved quality of health care to manage pain, nausea, vomiting, diarrhea, and bleeding (where analgesics such as morphine and oxycodone and antiemetics such as ondansetron and aprepitant are administered to allow for a more aggressive treatment regimen).

[0252] In some embodiments, the antibody or fragment thereof of the present invention can be combined with conventional methods of enhancing the immune function of the host. These include, but are not limited to, (i) enhancing APCs, for example, by (a) injecting DNA encoding heterologous MHC alloantigens into tumors, or (b) transfecting biopsied tumor cells with genes that enhance the possibility of immune antigen recognition (e.g., immune stimulatory cytokines, GM-CSF, costimulatory molecule B7.1, and costimulatory molecule B7.2), and (ii) adoptive cellular immunotherapy, or activated tumor-specific T cell therapy. Adoptive cellular immunotherapy involves isolating tumor-infiltrating host T lymphocytes and stimulating the expansion and proliferation of the population in vitro, for example, via IL-2 or tumor or both; in addition, isolated dysfunctional T cells can be activated by in-vitro application of the antibody of the present invention, and then the activated T cells can be readministered to the host.

[0253] The various combination therapies described above can be further combined for treatment.

[0254] Further examples of combinations of anti-PD-L1 antibodies with other therapies or therapeutic agents can be found in WO2016 / 061142, WO2010 / 077634, US60 / 696426, US61 / 264061, WO2016 / 007235, etc.

[0255] Such combination therapy encompasses both combined administration (wherein two or more therapeutic agents are contained in the same or separate formulations) and separate administration (wherein administration of an antibody of the invention can occur before, simultaneously with, and / or after administration of the other therapy, e.g., a therapeutic agent or treatment). The antibody molecule and / or the other therapy, e.g., a therapeutic agent or treatment, can be administered during active disease or during remission or less active disease. The antibody molecule may be administered before, simultaneously with, after, or during remission of disease.

[0256] In one embodiment, the administration of the anti-PD-L1 antibody and the other therapy (treatment or therapeutic agent) occurs within about one month of each other, or within about one, two, or three weeks, or within about one, two, three, four, five, or six days.

[0257] In some embodiments, the antibody combinations described herein can be administered individually (e.g., as separate antibodies) or linked (e.g., as bispecific or trispecific antibody molecules).

[0258] It will be appreciated that either therapy may be practiced using the immunoconjugates of the invention in place of or in addition to anti-PD-L1 antibodies.

[0259] Combination therapy with anti-LAG-3 antibody In some embodiments, the anti-PD-L1 antibodies of the invention may be used therapeutically in combination with an anti-LAG-3 antibody.

[0260] In some embodiments, the anti-LAG-3 antibody of the invention is an anti-human LAG-3 antibody. In some embodiments, the anti-LAG-3 antibody of the invention is an IgG1 antibody or an IgG2 antibody or an IgG4 antibody. In some embodiments, the anti-LAG-3 antibody is a monoclonal antibody. In some embodiments, the anti-LAG-3 antibody is humanized. In some embodiments, the anti-LAG-3 antibody is a chimeric antibody. In some embodiments, at least a portion of the framework sequences of the anti-LAG-3 antibody are human consensus framework sequences. In one embodiment, the anti-LAG-3 antibody of the invention also comprises an antibody fragment thereof, preferably an antibody fragment selected from the group consisting of Fab, Fab', Fab'-SH, Fv, single chain variable fragment (e.g., scFv) or (Fab')2, single domain antibody, diabody (dAb), or linear antibody.

[0261] In certain embodiments, the anti-LAG-3 antibodies or antigen-binding fragments thereof of the invention comprise: (i) the three heavy chain complementarity determining regions (HCDRs) of the heavy chain variable region set forth in SEQ ID NO: 75, and / or (ii) the three light chain complementarity determining regions (LCDRs) of the light chain variable region set forth in SEQ ID NO: 76 The present invention relates to a method for producing a semiconductor device comprising the steps of:

[0262] In some embodiments, the anti-LAG-3 antibody or antigen-binding fragment thereof of the invention comprises a heavy chain variable region (VH) and / or a light chain variable region (VL), wherein: (i) the VH comprises complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, wherein HCDR1 comprises or consists of the amino acid sequence of SEQ ID NO: 69; HCDR2 comprises or consists of an amino acid sequence selected from SEQ ID NO: 70; HCDR3 comprises or consists of the amino acid sequence of SEQ ID NO: 71; and / or (ii) VL comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3, wherein LCDR1 comprises or consists of the amino acid sequence of SEQ ID NO: 72; LCDR2 comprises or consists of the amino acid sequence of SEQ ID NO: 73; and LCDR3 comprises or consists of an amino acid sequence selected from SEQ ID NO: 74.

[0263] In some embodiments, the anti-LAG-3 antibody or antigen-binding fragment thereof of the invention comprises a heavy chain variable region, VH, and / or a light chain variable region, VL, wherein: (a) the heavy chain variable region VH is (i) comprising or consisting of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence selected from SEQ ID NO: 75; (ii) comprising or consisting of an amino acid sequence selected from SEQ ID NO: 75; or (iii) comprises an amino acid sequence having one or more (preferably at most 10, more preferably at most 5, 4, 3, 2 or 1) amino acid mutations (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to an amino acid sequence selected from SEQ ID NO: 75, and preferably these amino acid mutations are not present within the CDRs; and / or (b) the light chain variable region VL is (i) comprising or consisting of an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence selected from SEQ ID NO: 76; (ii) comprising or consisting of an amino acid sequence selected from SEQ ID NO: 76; or (iii) comprises an amino acid sequence having one or more (preferably at most 10, more preferably at most 5, 4, 3, 2 or 1) amino acid mutations (preferably amino acid substitutions, more preferably conservative amino acid substitutions) compared to an amino acid sequence selected from SEQ ID NO: 76, and preferably these amino acid mutations are not present within the CDRs.

[0264] In some embodiments, the anti-LAG-3 antibody or antigen-binding fragment thereof of the invention comprises a heavy chain and / or a light chain, wherein: (a) the heavy chain is (i) comprising or consisting of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence selected from SEQ ID NO: 77; (ii) comprising or consisting of an amino acid sequence selected from SEQ ID NO: 77; or (iii) comprises an amino acid sequence having one or more (preferably at most 20 or 10, more preferably at most 5, 4, 3, 2 or 1) amino acid mutations (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to an amino acid sequence selected from SEQ ID NO: 77, preferably these amino acid mutations are not present in the CDRs of the heavy chain, more preferably these amino acid mutations are not present in the heavy chain variable region; and / or (b) the light chain is (i) comprising or consisting of an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence selected from SEQ ID NO: 78; (ii) comprising or consisting of an amino acid sequence selected from SEQ ID NO: 78; or (iii) comprises an amino acid sequence having one or more (preferably at most 20 or 10, more preferably at most 5, 4, 3, 2 or 1) amino acid mutations (preferably amino acid substitutions, more preferably amino acid conservative substitutions) compared to an amino acid sequence selected from SEQ ID NO: 78, and preferably, these amino acid mutations are not present in the CDRs of the light chain, and more preferably, these amino acid mutations are not present in the light chain variable region.

[0265] In some embodiments, the modifications of the anti-PD-L1 antibodies of the invention also apply to anti-LAG-3 antibodies.

[0266] Route of Administration and Dosage The antibody of the present invention (or pharmaceutical composition or immunoconjugate containing the antibody or any other therapeutic agent) may be administered by any suitable means, including parenteral, intrapulmonary, intranasal, and intralesional administration, when required for localized treatment. Parenteral injections include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Drugs may be administered by any suitable means, such as injections, e.g., intravenous or subcutaneous injections, to some extent for short-term or long-term treatment. Various dosing regimens are contemplated herein, including, but not limited to, single or multiple doses at multiple time points, bolus injection, and pulse infusion.

[0267] The appropriate dose of an antibody of the invention (when used alone or in combination with one or more other therapeutic agents) for preventing or treating disease will vary depending on the type of disease being treated, the type of antibody, the severity and progression of the disease, whether the antibody is being administered for prophylactic or therapeutic purposes, previous treatments, the patient's clinical history and response to the antibody, and the judgment of the attending physician. The antibody is suitably administered to the patient in a single dose or over a series of treatments.

[0268] In some embodiments, the dosage regimen is adjusted to provide the optimum desired response (e.g., therapeutic response). For example, a single bolus injection may be administered, or several individual doses may be administered over time, or the dose may be proportionally increased or decreased as indicated by the severity of the condition being treated. It is particularly advantageous to formulate parenteral compositions in unit dosage form for ease and uniformity of dosage administration. Unit dosage form, as used herein, refers to physically discrete units suitable as unitary doses for the subject being treated, each unit containing a predetermined amount of active compound calculated to produce the desired therapeutic effect in combination with the required pharmaceutical carrier. The details of the unit dosage form of the present invention depend directly on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the field of combining active compounds for sensitive therapy in individuals.

[0269] Dosages and schedules for the anti-PD-L1 antibody molecule can be determined by one of skill in the art. In certain embodiments, the anti-PD-L1 antibody molecule is administered by injection (e.g., subcutaneously or intravenously) at a dose of about 1-30 mg / kg, such as about 5-25 mg / kg, about 10-20 mg / kg, about 1-5 mg / kg, or about 3 mg / kg. Dosage schedules can range, for example, from once per week to once every 2, 3, or 4 weeks. In one embodiment, the anti-PD-L1 antibody molecule is administered every other week at a dose of about 10-20 mg / kg. In one embodiment, the anti-PD-L1 antibody molecule is administered every other week at a dose of about 5 mg / kg or less, about 4 mg / kg or less, about 3 mg / kg or less, about 2 mg / kg or less, or about 1 mg / kg or less, alone or in combination (e.g., in combination with an anti-LAG-3 antibody molecule). In one embodiment, the anti-PD-L1 antibody molecule is administered at a dose of about 1-5 mg / kg every other week, at a dose of about 1-4 mg / kg every other week, at a dose of about 1-3 mg / kg every other week, or at a dose of about 1-2 mg / kg every other week. In one embodiment, the anti-PD-L1 antibody molecule is administered alone or in combination (e.g. in combination with an anti-LAG-3 antibody molecule) at a dose of about 1-5 mg / kg every other week, at a dose of about 1-4 mg / kg every other week, at a dose of about 1-3 mg / kg every other week, or at a dose of 1-2 mg / kg every other week.

[0270] Methods and Compositions for Diagnosis and Detection In certain embodiments, any of the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein may be used for detecting the presence of PD-L1 in a biological sample. The term "detection" as used herein includes quantitative or qualitative detection, and exemplary detection may include immunohistochemistry, immunocytochemistry, flow cytometry (e.g., FACS), magnetic beads complexed with antibody molecules, ELISA, and PCR techniques (e.g., RT-PCR). In some embodiments, the biological sample is blood, serum, or other fluid sample of biological origin. In certain embodiments, the biological sample comprises cells or tissues. In some embodiments, the biological sample is derived from a proliferative or cancerous lesion.

[0271] In one embodiment, anti-PD-L1 antibodies are provided for use in diagnostic or detection methods. In another aspect, a method is provided for detecting the presence of PD-L1 in a biological sample. In certain embodiments, the method comprises detecting the presence of PD-L1 protein in the biological sample. In certain embodiments, the PD-L1 is human PD-L1. In certain embodiments, the method comprises contacting the biological sample with an anti-PD-L1 antibody as described herein under conditions that allow the anti-PD-L1 antibody to bind to PD-L1, and detecting whether a complex is formed between the anti-PD-L1 antibody and PD-L1. The formation of a complex indicates the presence of PD-L1. The method can be an in-vitro method or an in-vivo method. In one embodiment, the anti-PD-L1 antibody is used to select subjects suitable for treatment with an anti-PD-L1 antibody, e.g., PD-L1 is a biomarker for selecting subjects.

[0272] In one embodiment, the antibodies of the invention can be used to diagnose cancer or tumors in a subject, for example to assess (e.g., monitor) the treatment or progression, diagnosis and / or staging of a disease described herein (e.g., a proliferative or cancerous disease). In certain embodiments, labeled anti-PD-L1 antibodies are provided. Labels include, but are not limited to, labels or moieties that are directly detected (e.g., fluorescent labels, chromophore labels, electron-dense labels, chemiluminescent labels, and radioactive labels) and moieties that are indirectly detected, such as an enzyme or ligand, for example, by enzymatic reaction or molecular interaction. Exemplary labels include, but are not limited to, 32 P, 14 C. 125 I, 3 H, and 131These include radioisotopes of I, fluorophores (e.g., rare earth chelates or luciferin and its derivatives), rhodamine and its derivatives, dansyl, umbelliferone, luciferase (e.g., firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456)), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HR), alkaline phosphatase, β-galactosidase, glucoamylase, lysase, carbohydrate oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (e.g., uricase and xanthine oxidase), enzymes that utilize hydrogen peroxide to oxidize dye precursors (e.g., HR, lactoperoxidase, or microperoxidase), biotin / avidin, spin labels, phage labels, stable free radicals, and the like.

[0273] In some embodiments of the invention provided herein, the sample is obtained prior to treatment with an anti-PD-L1 antibody. In some embodiments, the sample is obtained prior to treatment with an anti-cancer drug. In some embodiments, the sample is obtained after the cancer has metastasized. In some embodiments, the sample is a formalin-fixed, paraffin-embedded (FFPE) sample. In some embodiments, the sample is a biopsy (e.g., a core biopsy) specimen, a surgical specimen (e.g., a specimen from a surgical resection), or a fine needle aspirate.

[0274] In some embodiments, PD-L1 is detected prior to treatment, for example, prior to the first treatment or prior to treatment a period of time after a particular treatment.

[0275] In some embodiments, methods are provided for treating a tumor or an infection, the methods comprising detecting the presence of PD-L1 in a subject (e.g., using a sample, e.g., a sample containing cancer cells from the subject), thereby determining a PD-L1 level; comparing the PD-L1 level to a control level; and if the PD-L1 level is greater than the control level, administering to the subject a therapeutically effective amount of an anti-PD-L1 antibody (e.g., an anti-PD-L1 antibody described herein), optionally in combination with one or more other therapies, thereby treating the tumor or infection.

[0276] Exemplary Sequences of Anti-PD-L1 Antibodies of the Invention

[0277] [Table 6] JPEG2024164038000008.jpg248150 [Table 7] JPEG2024164038000010.jpg251140 [Table 8] JPEG2024164038000012.jpg251166 JPEG2024164038000013.jpg250162 JPEG2024164038000014.jpg249163 JPEG2024164038000015.jpg251153 [Table 9]

[0278] These and other aspects and embodiments of the present invention are described in the drawings (following the brief description of the drawings) and the detailed description of the invention below, and are illustrated in the examples below. Any or all of the features discussed above and throughout this application can be combined in various embodiments of the present invention. The following examples further illustrate the present invention. However, it should be understood that these examples are provided by way of illustration and not by way of limitation, and that various modifications may be made by those skilled in the art. EXAMPLES

[0279] Example 1 Preparation of hybridoma cells Hybridoma technology is a method of fusing two cells while maintaining the main characteristics of both. These two cells refer to mouse spleen cells and mouse myeloma cells immunized with an antigen. Mouse spleen cells (B lymphocytes) immunized with a specific antigen have the characteristics of antibody secretion function, but cannot be subcultured in vitro. Mouse myeloma cells can divide and grow infinitely under culture conditions, that is, they are so-called immortalized. Under the action of a selection medium, only the hybrid cells formed by fusing myeloma cells and B cells can have the ability to be subcultured, and a cell clone with both antibody secretion function and immortalization is formed. In one experiment, a mouse was immunized with hPD-L1 protein, and the mouse spleen cells and myeloma cells were obtained and fused, which resulted in hybridoma cells with positive antibody expression ability.

[0280] Hybridoma fusion

[0281] [Table 10]

[0282] Preparation for electroporation: Dishes were thoroughly soaked in 70% ethanol and allowed to dry in an ultraclean bench for use.

[0283] Isolation of splenocytes: Mice were sacrificed by cervical dislocation, sterilized with 75% alcohol for 5 minutes, and immediately placed in left lateral position on a mouse dissection plate in an ultraclean bench, and the four limbs of the mouse were fixed with a No. 7 needle; the spleen was removed after aseptically opening the abdominal cavity, and then washed with basal medium (prepared according to the table below). The surrounding connective tissue was carefully removed. The spleen was then transferred to another dish containing basal medium; the spleen was pressed down with an elbow needle and punctured with a small needle, and then pressure was applied with forceps to completely release the splenocytes to obtain a splenocyte suspension; after filtering with a 100 μM cell strainer, the cell suspension was washed once with 30 mL of basal medium and centrifuged at 1200 rpm for 6 minutes.

[0284] [Table 11]

[0285] Lysis of red blood cells: The supernatant was discarded and the cells were resuspended in 10 mL of RBC lysis buffer (GIBCO). Then, 20 mL of RBC lysis buffer was added; the suspension was left to stand for 5 minutes and centrifuged at 1100 rpm for 6 minutes. After removing the supernatant, the cells were resuspended in 10 mL of basal medium. Then, 30 mL of basal medium was added and the cells were centrifuged at 1100 rpm for 6 minutes; after removing the supernatant, the cells were resuspended in 20 mL of basal medium and counted.

[0286] Electroporation: SP2 / 0 cells (mouse myeloma cells) (ATCC) were resuspended in 20 mL of basal medium and counted; SP2 / 0 cells and splenocytes were mixed in a ratio of 1:2 to 1:1 and centrifuged at 100 rpm for 6 min; after removing the supernatant, the mixed cells were resuspended in 10 mL of fusion buffer (BTXpress); then 15 mL of fusion buffer was added, the mixture was centrifuged at 1000 rpm for 5 min, and the supernatant was discarded; after repeating the above steps, the cells were resuspended in an appropriate amount of fusion buffer solution to achieve a mixed cell density of 1 × 10 7 The cell suspension was adjusted to 100 mM MgCl2 / mL. The electroporation apparatus settings were as follows: 2 mL of cell suspension was added to each dish for electroporation.

[0287] [Table 12]

[0288] Post-fusion seeding: Leave the cells in the dish at room temperature for 5 minutes; transfer the cells to a centrifuge tube and dilute them with selection medium (prepared according to the table below) to 1-2 × 10 4 The cells were cultured at 100μL / mL. 100μL of cell suspension was added to each well of a 96-well plate. The selection medium was changed 7 days after fusion. The cells were screened on day 10 of incubation (or later depending on the proliferation status of the cells). Hybridoma cells expressing specific anti-PD-L1 antibodies were selected by FACS [FACS ARIA (BD Biosciences)].

[0289] [Table 13]

[0290] Subcloning of positive hybridoma cells Subcloning: 200 μL of the above basic medium was added to each well of columns 2 to 8 of a 96-well plate; a suspension was made with cells from the selected positive wells and added to column 1; 100 μL of the cell suspension from column 1 was transferred to column 2, and 100 μL of the mixture was transferred to the next column after mixing the wells. The above steps were repeated until 300 μL of the mixture was obtained in the final column. After standing for 15 minutes, the cells were counted under a microscope. An equivalent volume containing about 100 cells was added to 20 mL of the above basic medium for mixing and seeding in each well of 200 μL. After one week, the cells were observed under a microscope. The monoclonal wells were marked and the positive wells were detected.

[0291] Cryopreservation of cells: The status of the cells was monitored. Growth wells with viability above 90% were centrifuged at 1000 rpm for 5 min and the supernatant was discarded; the cells were cryopreserved at 1×10 7The cells were resuspended at 100 cells / mL, dispensed into cryopreservation tubes, placed in a programmable cooling container, and cryopreserved at -80°C.

[0292] Example 2: Production and purification of chimeric antibodies Using molecular biotechnology, the present invention produces an antibody sequence in anti-PD-L1 positive hybridoma cells, and uses the antibody sequence to construct a human-mouse chimeric antibody.

[0293] Sequencing of hybridomas RNA extraction: Fresh cells were centrifuged at 300g for 5 min and the supernatant was discarded. 500μL of LY buffer (Biomiga) (20μL of β-mercaptoethanol per mL before use) was added to the sediment and shaken until clear. The mixture was transferred to a centrifuge tube and centrifuged at 13000rpm for 2 min. The flow-through was collected. 100% ethanol was added to the flow-through in a 1 / 2 ratio and the fluid was mixed for 5 min until a clear solution was obtained. The clear solution was added to an RNA collection tube and centrifuged at 13000rpm for 1 min and the liquid portion was discarded. 500μL of regeneration buffer (Takara) was added and the mixture was centrifuged at 13000rpm for 30 s and centrifuged for another 30 s after adding 500μL of RNA wash buffer (Biomiga) (ethanol added before use). The above steps were repeated followed by centrifugation and evaporation to completely remove the ethanol. The collection column was pretreated with 30 μL of DEPC-treated water, the mixture was centrifuged at 12000 g for 2 minutes, and the eluate was collected. The RNA concentration was measured.

[0294] Generation of cDNA by reverse transcription: Reaction system I was constructed as follows.

[0295] [Table 14]

[0296] After incubation at 65° C. for 5 min, the system was quickly cooled on ice; the following reverse transcription system was added to reaction system I in a total volume of 20 μL.

[0297] [Table 15]

[0298] After gentle mixing, reverse transcription was induced at 42° C. for 60 min and then at 95° C. for 5 min. The mixture was then cooled on ice before cDNA recovery.

[0299] Connection of cDNA and T vector: The heavy chain variable region and the light chain variable region were amplified by PCR. The PCR reaction system contained the following components:

[0300] [Table 16]

[0301] The PCR reaction conditions were as follows: [Table 17]

[0302] 0.5 μL of pMD20-T vector (Clontech) and 5 μL of Ligation Mighty Mix (Takara) were added to 4.5 μL of PCR product from the PCR reaction. The mixture was gently mixed and incubated at 37° C. for 2 hours to obtain the ligation product.

[0303] Cell transformation: TOP10 competent cells [Tiangen Biotech (Beijing) Co.,Ltd.] were removed from -80°C and thawed on ice. 5 μL of the resulting ligation product was added to the thawed TOP10 competent cells. The mixture was shaken and incubated on ice for 30 min. After a 90 s heat shock at 42°C, the resulting mixture was quickly cooled on ice for 2 min. 900 μL of LB culture medium [Sangon Biotech (Shanghai) Co.,Ltd.] was added to the EP tube, and the mixture was incubated at 37°C on a shaker at 220 rpm for 1 h. The bacteria were centrifuged at 3000g for 2 min. 800 μL of the supernatant was removed, and the bacteria were resuspended in the remaining medium for incubation on ampicillin plates. The bacteria were incubated overnight at 37°C. Clones were isolated for sequencing.

[0304] Construction of chimeric antibodies The sequenced VH and VL regions of the mouse anti-PD-L1 antibody generated from the hybridoma in Example 1 were amplified by PCR: the sequences of the upstream and downstream primers are shown in Tables 5 and 6.

[0305] [Table 18]

[0306] After mixing the components according to ratio, the resulting primer mix 1 was used for subsequent VH PCR amplification.

[0307] [Table 19] JPEG2024164038000027.jpg147156

[0308] After mixing the components according to ratio, the resulting primer mix 2 was used for the subsequent VL PCR amplification.

[0309] The PCR system was as follows:

[0310] [Table 20]

[0311] The gel was excised to recover the PCR amplified products.

[0312] Homologous recombination: The homologous recombination system was constructed as follows.

[0313] [Table 21]

[0314] After incubation at 37°C for 30 minutes, the recombinant product was obtained. TOP10 competent cells were transformed with the recombinant product, and monoclones were isolated for sequencing. Clones containing the plasmid in the correct insert orientation were selected as positive clones and retained.

[0315] Expression and purification of chimeric antibodies Plasmids containing the anti-PD-L1 antibody sequence were extracted from the positive clones obtained above.

[0316] 293F cells (Invitrogen) were subcultured according to the desired transfection volume, and the day before transfection, a cell density of 1.5 × 10 6 The cell density on the day of transfection was approximately 3 × 10 6The transfection volume was 1:10 cells / mL. An appropriate amount of plasmid was added to F17 culture medium (Gibco, A13835-01) at 1 / 10 of the final volume as transfection and mixed. An appropriate amount of polyethyleneimine (PEI) (Polysciences, 23966) was added to this mixture (plasmid:PEI=1:3 ratio for 293F cells), mixed, and incubated at room temperature for 10 minutes to obtain a DNA / PEI mixture. After resuspension in the DNA / PEI mixture, cells were transfected at 36.5°C and 8% CO2. After 24 hours, FEED (Sigma) was added to these cells at 2% of the transfection volume and incubated at 36.5°C, 8% CO2, 120 rpm. Subculture was continued until the 6th day of subculture or until the viability was below 60%, and the cells were centrifuged and the supernatant was collected and purified.

[0317] The gravity column for purification was treated with 0.5 M NaOH overnight and then dried at 180°C for 4 hours to prepare the purification column. The glassware was washed with distilled water and dried. Before purification, the harvested culture was centrifuged at 4500 rpm for 30 minutes and the cells were discarded. The supernatant was filtered through a 0.22 μL filter. Each tube was loaded with 1 mL of protein A and equilibrated with 10 mL of binding buffer (sodium phosphate 20 mM, NaCl 150 mM, pH 7.0). The filtered supernatant was loaded onto the purification column and then re-equilibrated with 15 mL of binding buffer. 5 mL of elution buffer (citric acid + sodium citrate 0.1 M, pH 3.5) was added. The eluate was collected and 80 μL of Tris-HCl was added per mL of eluate. The recovered antibody was buffer exchanged into PBS (Gibco, 70011-044) by ultrafiltration / diafiltration and the concentration was measured.

[0318] The CDRs, light and heavy chain variable regions, and light and heavy chain amino acid sequences of the four obtained chimeric antibodies of the present invention, as well as their SEQ ID NOs, are shown in Tables 1 to 3 above.

[0319] The reference antibody used in the present invention is Roche's PD-L1 antibody atezolizumab (hereinafter referred to as ATE or Ate, or trademark: Tecentriq), and its CDRs, light chain and heavy chain variable regions, and light chain and heavy chain amino acid sequences are also shown in Tables 1 to 3 above.

[0320] Example 3 Binding kinetics of chimeric antibodies to antigens determined by biological optical interferometry The equilibrium dissociation constant (K D ) was determined by biological optical interferometry (ForteBio). A conventional ForteBio affinity assay was performed (Estep, P., et al, High throughput solution based measurement of antibody-antigen affinity and epitope binning. MAbs, 2013.5(2):270-8).

[0321] Thirty minutes before the experiment, an appropriate number of AMQ (Pall, 1506091) sensors (for sample detection) or AHQ (Pall, 1502051) sensors (for positive control detection) depending on the number of samples were immersed in SD buffer (PBS 1×, BSA 0.1%, Tween-20 0.05%).

[0322] 100 μL each of SD buffer, antibody, and antigen (including human PD-L1, mouse PD-L1, and macaca fascicularis PD-L1, all purchased from Acrobiosystems) were added to a 96-well black polystyrene half-area microplate (Greiner, 675076). The sensors were arranged according to the location of the samples. The instrument settings were as follows: the run steps were baseline, loading ~1 nm, baseline, association, and dissociation. The run time of each step depended on the rate of association and dissociation. The rotation speed was 400 rpm and the temperature was 30 °C. K D Values ​​were analyzed using ForteBio analysis software.

[0323] The affinities of antibodies 3-266.1, 4-79.2, 4-26.6, and 4-48.5 in the above assays are shown in Table 7.

[0324] [Table 22]

[0325] In the above assay, the K D The values ​​are 9.80E -10 M, 7.56E -09 M, 3.85E -09 M, and 1.23E -09 The antibodies in this study had comparable or superior K D had value.

[0326] Example 4 Binding assay of chimeric antibodies and cells overexpressing PD-L1 In this study, the binding of gradient dilutions of chimeric antibodies of the invention to stable CHO cell lines overexpressing human PD-L1 on the cell surface was measured by flow cytometry.

[0327] CHO cells overexpressing human PD-L1 (CHO-PDL1) were generated by transfecting CHO-S cells (Invitrogen, ExpiCHO™ Expression System Kit, catalog no. A29133) with the pCHO1.0 vector (Invitrogen) harboring human PD-L1 cDNA (Sino biological) cloned into the multiple cloning site (MCS).

[0328] Count CHO-PDL1 cells and place them at 1 x 10 6The cells were diluted to 100 μL / well and added to each well of a U-bottom 96-well plate at 100 μL / well. The suspension was centrifuged at 400 g for 5 minutes and the supernatant was discarded. The samples (chimeric antibodies 3-266.1, 4-79.2, 4-26.6 and 4-48.5, respectively, and the positive control Ate) (the antibodies were serially diluted 3-fold from 500 nM to 1 / 8 in PBS containing 0.1% bovine serum albumin (BSA)) were added to the U-shaped plate. The cells were resuspended to a volume of 100 μL / well and then placed on ice for 30 minutes. The suspension was centrifuged at 400 g for 5 minutes and the supernatant was discarded. The cells were washed once with PBS. The mixture was centrifuged at 400 g for 5 minutes and the supernatant was discarded. 100 μL of FITC-labeled secondary antibody against anti-mouse-Fab (Jackson Immuno Research) (diluted 1:500 in PBS) was added to each well, and 100 μL of FITC-labeled secondary antibody against anti-human-Fab (Jackson Immuno Research) was added to the positive control antibody-treated cells. The cells were incubated in the dark on ice for 30 minutes. The cells were centrifuged at 400 g for 5 minutes, the supernatant was discarded, and washed once with PBS. The cells were resuspended in 100 μL of 1×PBS and detected by FACS.

[0329] The binding of antibodies 3-266.1, 4-79.2, 4-26.6 and 4-48.5 to CHO-PDL1 cells in the above assay is shown in FIG.

[0330] In the above assay, antibodies 3-266.1, 4-79.2, 4-26.6, and 4-48.5 all bound to human PD-L1 overexpressed on CHO cells and inhibited EC 50 were 2.139 nM, 2.598 nM, 1.985 nM, and 1.995 nM, respectively. Compared to the reference antibody ATE, antibodies 3-266.1, 4-79.2, 4-26.6, and 4-48.5 had superior affinity, with some antibodies having binding capacities more than twice that of the reference antibody.

[0331] Example 5 Humanization of Chimeric Antibodies The chimeric antibodies obtained in Example 1 were humanized. The humanization of the antibodies was carried out by using the proprietary software program SmrtMolHumanize from Macromoltek. The sequences were entered into the software, and the system generated a three-dimensional model of these sequences. These sequences were then humanized by the following steps: 1) Determine the structure of the CDR loops; 2) searching the human germline sequence database for the closest homologous sequences for each heavy and light chain V / J region; 3) screening human germline for those with the highest similarity to the heavy and light chains and the least amount of back mutations; 4) constructing the CDR regions of a chimeric antibody on the backbone of a human antibody; 5) determining the positions of amino acids in the scaffold that maintain CDR function based on sequence and structural features; 6) adding back mutations (back to the input amino acids) at key positions in the sequence; 7) creating a three-dimensional model of the humanized sequence; 8) Manually inspect the sequence and structure to identify risk sites that may result in misfolding or reduced stability; 9) Optimize amino acids at risk sites.

[0332] The CDRs, light and heavy chain variable regions, and light and heavy chain amino acid sequences of the four obtained chimeric antibodies of the present invention (HZ3266-IgG1N297A, HZ3266-IgG1, HZ3266-IgG4PAK, and HZ4485-IgG1N297A) are shown in Tables 1 to 3 above.

[0333] Example 6 Binding kinetics of humanized antibodies to antigens determined with ForteBio The equilibrium dissociation constants (K D) was determined in ForteBio. The ForteBio affinity assay is shown in Example 2. The affinities of antibodies HZ3266-IgG1N297A, HZ3266-IgG1, HZ3266-IgG4PAK, and HZ4485-IgG1N297A in the above assays are shown in Table 8.

[0334] [Table 23]

[0335] In the above assay, the humanized antibodies HZ3266-IgG1N297A, HZ3266-IgG1, HZ3266-G4PAAK and HZ4485-IgG1N297A described herein each had an EEG response of 7.24 E -10 M, 9.35E -10 M, 1.32E -09 M, and 3.17E -09 K of M D values, and the humanized antibodies in this study had comparable or superior K values ​​compared to the reference. D had value.

[0336] Example 7 Binding assay of humanized antibodies with cells overexpressing PD-L1 In this study, the binding of gradient-diluted humanized antibodies of the present invention to a stable CHO cell line overexpressing human PD-L1 on the cell surface (CHO-PDL1) was measured by flow cytometry. The assay was described in Example 3, except that the antibodies used were humanized antibodies HZ3266-IgG1N297A, HZ3266-IgG1, HZ3266-G4PAAK, and HZ4485-IgG1N297A. These antibodies were serially diluted 3-fold from a concentration of 500 nM to one-eighth concentration in PBS containing 0.1% bovine serum albumin (BSA). The binding conditions for humanized antibodies HZ3266-IgG1N297A, HZ3266-IgG1, HZ3266-G4PAAK, HZ4485-IgG1N297A, and CHO-PDL1 are shown in Figure 2.

[0337] In this assay, humanized antibodies HZ3266-IgG1, HZ3266-IgG1N297A, HZ3266-G4PAAK, and HZ4485-IgG1N297A bound to human PD-L1 overexpressed on CHO cells with EC50 of 1.813nM, 1.784nM, 1.862nM, and 1.561nM, respectively. Compared to the reference antibody ATE, these antibodies had superior binding ability.

[0338] Example 8 Detection of antibody biological activity by MOA Anti-PD-1 / PD-L1 antibodies can reduce the inhibitory effect on the downstream NFAT signal pathway by blocking the binding of PD-1 and PD-L1. In this study, the MOA detection system available from Promega (PD-1 / PD-L1 Blockade Bioassay, Cell Propagation Model, Catalog J1252) was used. According to the method indicated in the product manual, the expression of the fluorescent reporter gene was detected, thereby indicating the activation of NFAT signaling by detecting the inhibitory effect of the antibody on the binding of PD-1 and PD-L1.

[0339] CHOK1-PDL1 cells (from the MOA detection system described above) were seeded 1 day before the activity assay. The cells were subcultured 1–2 days before seeding. The culture supernatant was discarded and the cells were washed once with PBS (Gibco). An appropriate amount of trypsin (Gibco) was added for digestion at 37°C and 5% CO2 for 3–5 min; a 4-fold volume of culture medium as trypsin was added and these cells were transferred to a 50 mL centrifuge tube and counted. The desired volume of cells was centrifuged at 230 g for 10 min. The cells were added to 1640 culture medium (Gibco) and 4 × 10 5 The cells were resuspended at 100 μL / well to 300 cells / mL. The cells were transferred to a 96-well white culture plate (Nunclon) at 100 μL / well. PBS was added to the edge wells at 200 μL / well. The cells were incubated overnight in an incubator at 37° C. with 5% CO2.

[0340] Processing of Jurkat-PD1 cells (from MOA detection system above): Cells were subcultured 2 days prior to activity assay. After counting, the desired volume of cells was centrifuged at 170g for 5 min. Cells were diluted in assay buffer [1640 culture medium (Gibco) + 1% FBS] at 1.25 × 10 6 The cells were resuspended at 100 cells / mL.

[0341] Addition of samples and Jurkat-PD1 cells to the assay plate (from the MOA detection system described above): 95 μL / well of CHOK1-PDL1 cell supernatant was discarded. 40 μL of sample [humanized antibodies HZ3266-IgG1, HZ3266-IgG1N297A and HZ4485-IgG1N297A made in the present invention, positive control (Ate) and negative control (IgG1)] was added [these antibodies were serially diluted 3-fold from 100 nM to 1 / 8 concentration in assay buffer]. 40 μL of Jurkat-PD1 cells were added. Cells were incubated in an incubator at 37°C, 5% CO2 for 6 hours.

[0342] Detection: Bio-Glo™ Buffer (from the MOA Detection System above) was pre-thawed and Bio-Glo™ Substrate (from the MOA Detection System above) was added and mixed well. After 6 hours, Bio-Glo™ Reagent (from the MOA Detection System above) was added at 80 μL / well. The resulting mixture was left at room temperature for 5-10 minutes before reading.

[0343] In this assay, as shown in Figure 3, antibodies HZ3266-IgG1, HZ3266-IgG1N297A, and HZ4485-IgG1N297A could effectively block PD1 / PD-L1 interaction.

[0344] Example 9 Mixed Lymphocyte Reaction In this study, we co-incubated the antibodies with mature DC cells and CD4+ T cells derived from different donors, and detected the relative expression levels of IL2 and IFN-γ in this system to reflect the activation effects of various antibodies on T cells.

[0345] Isolation of PBMC: 50 mL of fresh blood from a donor was added to 2.5x PBS. This mixture was gently added to Ficoll (Thermo) and aliquoted into 4 tubes, 12.5 mL each. These samples were centrifuged at 400g for 30 min and then stopped at a deceleration of 0. The middle white strip was pipetted into PBS and washed twice with PBS.

[0346] Isolation of DC cells: The PBMC cells isolated above were incubated for adhesion at 37°C, 6% CO2 for 2 hours after adding 5mL of T cell culture medium (prepared according to the table below). The cell suspension was pipetted for isolation of CD4+ cells. 3mL of DC culture medium (prepared according to the table below) was added to the remaining cells for 2 days of incubation, followed by another 3mL of DC culture medium. On the fifth day of culture, rTNFa (R&D Systems) (1000U / mL), IL-1b (R&D Systems) (5ng / mL), IL-6 (R&D Systems) (10ng / mL) and 1μM PGE2 (Tocris) were added for another 2 days of incubation to obtain DC cells for mixed lymphocyte reaction (MLR).

[0347] [Table 24]

[0348] CD4+ T cell isolation: This was done according to the instructions of the "Untouched CD4+ T cell isolation" kit (11346D, Invitrogen). After leaving the PBMCs for 2 hours, the cell suspension was transferred with a pipette into a 15 mL centrifuge tube. The cells were centrifuged at 200 g for 10 minutes and the sediment was resuspended in 500 μL of isolation medium, 100 μL of AB serum and 100 μL of purified antibodies. This mixture was incubated for 20 minutes at 4°C and washed once with isolation medium. 500 μL of bead buffer (Invitrogen) was added for a 15 minute incubation and then the beads were removed by a magnetic field. This mixture was washed once with T cell culture medium and resuspended in 8 mL of culture medium. The resulting mixture was then incubated at 37°C and 6% CO2.

[0349] MLR: The mature DC cells and CD4+ cells obtained above were mixed at 200μL / well, with 10000 DC cells and 100000 CD4+ cells. The antibody of the present invention (concentration: 100nM, 20nM, 4nM, 0.8nM, 0.16nM and 0.032nM) was added. The mixture of DC cells prepared above (referred to as DC in the table below), CD4+T cells (referred to as CD4 in the table below), the mixture of DC cells and CD4+ cells (referred to as cells in the table below), as well as IgG1 disclosed in Table 3 used as a negative control here, and DC + CD4+T cells + anti-CD3 / CD28 magnetic beads (QIAGEN) (referred to as beads in the table below) used as a positive control. These samples were incubated for 5 days, and the concentrations of IL2 and IFN-γ (relative expression ΔF%) were detected by cisbio kits (human IL2 kit 1000 test, human IFNγ 1000 test).

[0350] The results are shown in Tables 9, 10, 11, and 12 and Figures 4 and 5. The data in the tables are ΔF%.

[0351] [Table 25]

[0352] [Table 26]

[0353] [Table 27]

[0354] [Table 28]

[0355] Therefore, the antibody of the present invention can effectively activate T cells in vitro, and the activation effect is better than that of the positive control antibody.

[0356] Example 10. Assay of Antibody Druggability with Zenix Column In this assay, antibody druggability was detected by analyzing the retention time of an exemplary humanized antibody of the present invention on a Zenix column (Sepax Technologies, Inc.). The shorter the retention time, the lower the viscosity of the antibody and the better its druggability.

[0357] Chromatographic conditions: wavelength: 214 nm, column temperature: 25° C., flow rate: 0.35 mL / min, injection volume: 10 μL.

[0358] Sample preparation: 100 μL of sample (antibodies HZ3266-IgG1, HZ3266-IgG4PAAK, HZ3266-IgG1N297A, and HZ4485-IgG1N297A; ATE concentration 1 mg / mL as positive control) was centrifuged at 13000 rpm for 5 min. 80 μL of supernatant was transferred to the liquid phase insert and placed in the liquid phase sample tray for injection.

[0359] As shown in Table 13, the retention times of the various HZ3266 isotypes and HZ4485 on the column were shorter than the reference antibodies, indicating good druggability of antibodies HZ3266 and HZ4485.

[0360] [Table 29]

[0361] Example 11 Antitumor Efficacy Assay In this assay, the anti-tumor effects of PD-L1 antibodies of the invention were tested in MC38 cells expressing human PD-L1 in hPD-L1 transgenic mice (MC38-hPDL1) (Nanjing Yinhe Biotech).

[0362] hPD-L1 transgenic mice: Female hPD-L1 transgenic mice (approximately 8 weeks old) on a C57Bl / 6 background were purchased from Shanghai Model Organisms Center, Inc. Mice were allowed to adapt for 7 days after arrival before testing.

[0363] cell: MC38 cells expressing human PD-L1 (MC38-hPDL1) were purchased from Nanjing Yinhe Biotech and subcultured strictly according to the instructions for further in vivo assays. Cells were harvested by centrifugation and resuspended in sterile PBS to a cell density of 5 × 10 6 The cell concentration was adjusted to 1000 cells / mL. On day 0, 0.2 mL of the cell suspension was implanted subcutaneously into the abdominal region of hPD-L1 transgenic mice to establish the MC38-hPDL1 tumor-bearing mouse model.

[0364] Dosage: The tumor volume of the mice was measured 6 days after implantation and was 87.4 mm 3 ~228.4mm 3Mice with tumor volumes ranging from 0.01 to 0.01 were selected and divided into groups evenly according to tumor volume (8 mice per group, one receiving IgG1 and the other receiving HZ3266-IgG1N297A of the present invention). Mice were treated twice weekly on days 6, 10, 14, 17, 21, 24, 28, 31 and 35 after implantation. The doses and routes of administration are shown in Table 12. During the treatment period, mice were monitored for changes in tumor volume and body weight twice weekly for 5 weeks. Body weight and tumor volume were measured before each administration. Measurement of tumor volume: The maximum length of the long axis (L) and the maximum length of the short axis (W) of the tumor were measured with a vernier caliper, and tumor volume was calculated according to the following formula: V=L×W 2 The weight of the mice was measured twice a week using an electronic balance.

[0365] [Table 30]

[0366] The antibodies of the invention demonstrated significant anti-tumor efficacy one week after administration ( FIG. 6 ), and the tumor in one mouse that received the antibodies of the invention completely regressed by day 35. These results showed that administration of the various antibodies did not affect the body weight of tumor-bearing mice.

[0367] Therefore, the antibody of the present invention has a clear inhibitory effect on tumors.

[0368] Example 12 Combination of anti-PD-L1 antibodies of the invention with anti-human LAG-3 antibodies In this study, the anti-tumor activity of a combination of an anti-PD-L1 antibody (HZ3266-IgG1N297A) and an anti-human-LAG-3 antibody (ADI-31853) was tested in a humanized mouse model.

[0369] In this study, the anti-PD-L1 antibody was tested for its antitumor efficacy in NCG mice bearing A375 (ATCC) human skin cancer cells. Human PBMCs (whole cells) (2 × 10 6A375 tumor-bearing mouse model was established by intravenously injecting A375 cells / mouse, followed by subcutaneous implantation. After tumor formation, the mice were divided into groups and treated with different antibodies. During the treatment period, the changes in tumor size and mouse weight were monitored. Treatment was administered twice a week for 2 weeks, with a total of 5 doses. The mice were monitored twice a week for 4 weeks. The doses and routes of administration were as follows: Tumor growth inhibition (TGI%) was calculated after the end of treatment.

[0370] Anti-human LAG-3 antibody ADI-31853 The cDNA encoding the light and heavy chain amino acid sequences of the anti-LAG-3 antibody ADI-31853 (Table 3) was cloned into the expression vector pTT5 according to methods known in the art.

[0371] The expression vector containing the target antibody gene and the transfection reagent PEI (Polysciences) were transiently transfected into incubated human embryonic kidney 293 (Invitrogen) cells according to the scheme provided by the manufacturer. After transfection, the supernatant was discarded and the cells were resuspended in fresh EXPI293 medium (Gibco) at 4 × 10 6 The cells were incubated at 37° C., 5% CO2 for 7 days, feeding with fresh medium every 48 hours. After 7 days, the cells were centrifuged at 1300 rpm for 20 minutes. The supernatant was purified with Protein A, producing antibodies with a purity of >95%.

[0372] The equilibrium dissociation constant (K D) was measured by biological optical interferometry (ForteBio). A conventional ForteBio affinity assay was performed (Estep, P., et al, High throughput solution based measurement of antibody-antigen affinity and epitope binning. MAbs, 2013.5(2):270-8). Briefly, the sensor was equilibrated offline with assay buffer for 30 min, and then online detection was performed for 60 s to establish a baseline. For the ForteBio affinity assay, purified antibodies obtained as described above were loaded online onto an AHQ sensor (ForteBio). The antibody-loaded sensor was then exposed to 100 nM human LAG-3 antigen (ArcoBiosystems) for 5 min, after which the sensor was transferred to dissociation assay buffer for 5 min for measurement of dissociation rates. Kinetic analysis was performed using a 1:1 binding model.

[0373] In the above assays, ADI-31853 affinities were as follows:

[0374] [Table 31]

[0375] mouse: Female NOG mice, weighing 17.6-24.2 g and 7-8 weeks old (age at the time of tumor cell transplantation), were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. Mice were adapted for 7 days after arrival before testing.

[0376] cell: Human skin cancer cells A375 (ATCC#CRL-1619) were purchased from ATCC and subcultured strictly according to the requirements provided by ATCC for further in-vivo assays. Cells were harvested by centrifugation and resuspended in sterile PBS to a cell density of 30 × 10 6After intravenous injection of human PBMCs (whole cells) into NOG mice, the right back was shaved and A375 cells were subcutaneously injected at 0.2 mL / mouse. The tumor volume of the mice was measured 7 days after implantation and was 70-71 mm. 3 Mice with tumor volumes ranging from 0.01 to 0.01 were selected and randomly divided into groups according to tumor volume.

[0377] treatment: The following antibodies were injected subcutaneously into the various groups: (1) Human IgG (Equitech-Bio), 20 mg / kg; (2) LAG-3(ADI-31853), 10mg / kg; (3) PD-L1(HZ3266-IgG1N297A), 10mg / kg; (4) LAG-3(ADI-31853), 10mg / kg+PD-L1(HZ3266-IgG1N297A), 10mg / kg.

[0378] Seven days after implantation, mice with acceptable mean tumor sizes were randomly divided into groups of eight mice each, and each group was dosed with one of four regimens at the doses listed above on days 7, 10, 14, and 17, respectively.

[0379] Analysis: Tumor volumes and body weights were measured twice a week during the study. Mice were euthanized when the tumor reached the endpoint or when the mice lost more than 20% of their body weight. The maximum length of the long axis (L) and the maximum length of the short axis (W) of the tumor were measured with a caliper, and tumor volume was calculated according to the following formula: V = L × W 2 The tumor volume over time for the different groups of mice was plotted. Statistical significance was determined using analysis of variance (ANOVA). For all analyses, a P value of less than 0.05 was considered statistically significant.

[0380] As shown in Figure 7, it can be seen that the combination of anti-LAG-3 monoclonal antibody ADI-31853 (31853) and anti-PD-L1 monoclonal antibody (HZ3266-IgG1N297A) (HZ3266) significantly inhibited tumor growth compared to the use of a human IgG control (equitech-Bio) (hIgG) and the use of these two antibodies individually.

Claims

1. An antibody or antigen-binding fragment thereof that binds to PD-L1, (i) three complementarity determining regions HCDRs of a heavy chain variable region as set forth in SEQ ID NO: 26 or 30 and three complementarity determining regions LCDRs of a light chain variable region as set forth in SEQ ID NO: 32 or 36; or (ii) three complementarity determining regions (HCDRs) of a heavy chain variable region as set forth in SEQ ID NO: 27 and three complementarity determining regions (LCDRs) of a light chain variable region as set forth in SEQ ID NO: 33; or (iii) three complementarity determining regions (HCDRs) of a heavy chain variable region as set forth in SEQ ID NO: 28 and three complementarity determining regions (LCDRs) of a light chain variable region as set forth in SEQ ID NO: 34; or (iv) three complementarity determining regions HCDRs of a heavy chain variable region represented by SEQ ID NO: 29 or 31, and three complementarity determining regions LCDRs of a light chain variable region represented by SEQ ID NO: 35 or 37 2. An antibody or antigen-binding fragment thereof comprising:

2. An antibody or antigen-binding fragment thereof that binds to PD-L1, the antibody comprising three complementarity determining regions (HCDRs) of a heavy chain variable region and three complementarity determining regions (LCDRs) of a light chain variable region, wherein: An antibody or antigen-binding fragment thereof, wherein HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 1, 2, 3, or 4; HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 5, 6, 7, 8, or 9; HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 10, 11, 12, or 13; LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, 15, or 16; LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 17, 18, 19, or 20; and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 21, 22, 23, 24, or 25.

3. An antibody or antigen-binding fragment thereof that binds to PD-L1, the antibody comprising a heavy chain variable region and / or a light chain variable region, The heavy chain variable region (i) the three complementarity determining regions (HCDRs) contained in the VH of any one of the antibodies listed in Table B; or (ii) a combination of HCDR1, HCDR2 and HCDR3 shown in Table A and / or The light chain variable region comprises: (i) the three complementarity determining regions (LCDRs) contained in the VL of any one of the antibodies listed in Table B; or (ii) a combination of LCDR1, LCDR2, and LCDR3 shown in Table A 2. An antibody or antigen-binding fragment thereof comprising:

4. the antibody comprises a light chain variable region and / or a heavy chain variable region, (i) the heavy chain variable region comprises or consists of an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NO: 26 or 30; and / or the light chain variable region comprises or consists of an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NO: 32 or 36; (ii) the heavy chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 27; and / or the light chain variable region comprises or consists of an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 33; (iii) the heavy chain variable region comprises or consists of an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 28; and / or the light chain variable region comprises or consists of an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 34; (iv) the heavy chain variable region comprises or consists of an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NO: 29 or 31; and / or The light chain variable region comprises or consists of an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NO: 35 or 37. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 3.

5. The antibody comprises a light chain variable region and / or a heavy chain variable region, (i) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 26 or 30; and / or the light chain variable region comprises the amino acid sequence of SEQ ID NO: 32 or 36; (ii) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:27; and / or the light chain variable region comprises the amino acid sequence of SEQ ID NO:33; (iii) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:28; and / or the light chain variable region comprises the amino acid sequence of SEQ ID NO:34; (iv) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 29 or 31; and / or The light chain variable region comprises the amino acid sequence of SEQ ID NO: 35 or 37. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 3.

6. The antibody (a) a heavy chain comprising or consisting of: (i) an amino acid sequence having at least 85% identity to an amino acid sequence selected from SEQ ID NOs: 38, 42, 43, or 44; or (ii) an amino acid sequence selected from SEQ ID NOs: 38, 42, 43, or 44; and / or (b) a light chain comprising or consisting of: (i) an amino acid sequence having at least 85% identity to an amino acid sequence selected from SEQ ID NO: 46 or 50; or (ii) an amino acid sequence selected from SEQ ID NO: 46 or 50; or (a) a heavy chain comprising or consisting of: (i) an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 39; or (ii) the amino acid sequence of SEQ ID NO: 39; and / or (b) a light chain comprising or consisting of: (i) an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 47; or (ii) the amino acid sequence of SEQ ID NO: 47; or (a) a heavy chain comprising or consisting of: (i) an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 40; or (ii) the amino acid sequence of SEQ ID NO: 40; and / or (b) a light chain comprising or consisting of: (i) an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 48; or (ii) the amino acid sequence of SEQ ID NO: 48; or (a) a heavy chain comprising or consisting of: (i) an amino acid sequence having at least 85% identity to an amino acid sequence selected from SEQ ID NO: 41 or 45; or (ii) an amino acid sequence selected from SEQ ID NO: 41 or 45; and / or (b) a light chain comprising or consisting of: (i) an amino acid sequence having at least 85% identity to an amino acid sequence selected from SEQ ID NO: 49 or 51; or (ii) an amino acid sequence selected from SEQ ID NO: 49 or 51 The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, comprising:

7. Features as below: (1) binds to PD-L1 (e.g., human PD-L1) with high affinity, e.g., binds to PD-L1 with an equilibrium dissociation constant (K D ) to bond; (2) The antibody or fragment thereof has an EC value of, for example, about 2 nM or less, that binds to cells expressing human PD-L1. 50 Combine with; (3) The antibody or fragment thereof inhibits PD-L1-associated activity with an EC 50 Block with; (4) the antibody or fragment thereof enhances T cell function better than, for example, known anti-PD-L1 antibodies, such as Tecentriq; (5) the antibody or fragment thereof enhances T cell proliferation, e.g., in an MLR, better than known anti-PD-L1 antibodies, e.g., Tecentriq; (6) the antibody or fragment thereof enhances IFN-γ secretion better than, e.g., known anti-PD-L1 antibodies, e.g., Tecentriq; (7) the antibody or fragment thereof enhances IL-2 secretion better than, for example, known anti-PD-L1 antibodies, such as Tecentriq; (8) A retention time (RT) of less than about 10 minutes in a Zenix column assay; (9) inhibiting one or more activities of PD-L1, e.g., resulting in one or more of the following: an increase in tumor-infiltrating lymphocytes, an increase in T cell receptor-mediated proliferation, or a decrease in immune evasion of cancer cells; (10) Inducing antibody-dependent cell-mediated cytotoxicity (ADCC); (11) exhibits the same or similar binding affinity and / or specificity for PD-L1 as any one of the antibodies listed in Table 3; (12) Inhibits (e.g., competitively inhibits) the binding of any one of the antibodies listed in Table 3 to PD-L1; (13) binds to the same or overlapping epitope as any one of the antibodies listed in Table 3; (14) competes for binding to PD-L1 with any one of the antibodies listed in Table 3; (15) Having one or more biological characteristics of any one of the antibodies listed in Table 3. The antibody or antigen-binding fragment thereof that binds to PD-L1 according to any one of claims 1 to 6, wherein the antibody or antigen-binding fragment has one or more of the following structure:

8. 8. The anti-PD-L1 antibody or antigen-binding fragment thereof of any one of claims 1 to 7, wherein the antibody is an antibody or antigen-binding fragment in the form of an IgG1 or IgG4, and optionally the anti-PD-L1 antibody or antigen-binding fragment thereof comprises a κ light chain constant region, e.g., a human κ light chain constant region.

9. The anti-PD-L1 antibody or antigen-binding fragment thereof of any one of claims 1 to 8, wherein the antibody is a monoclonal antibody.

10. The anti-PD-L1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, wherein the antibody is a humanized antibody, a human antibody, or a chimeric antibody.

11. The antigen-binding fragment may be a single chain antibody, such as Fab, Fab', Fab'-SH, Fv, scFv, (Fab') 2 The antibody or antigen-binding fragment thereof according to any one of claims 1 to 10, which is an antibody fragment selected from the group consisting of a fragment, a single domain antibody, a diabody (dAb), or a linear antibody.

12. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 11, wherein the antibody is a bispecific or multispecific antibody, preferably a bispecific antibody that binds to PD-L1 and LAG-3.

13. An isolated nucleic acid encoding the anti-PD-L1 antibody or antigen-binding fragment thereof of any one of claims 1 to 12.

14. A vector comprising the nucleic acid according to claim 13, preferably an expression vector such as the pTT5 vector.

15. 15. A host cell comprising a nucleic acid according to claim 13 or a vector according to claim 14, which is preferably a prokaryotic or eukaryotic cell, more preferably selected from the group consisting of an E. coli cell, a yeast cell, a mammalian cell or other cell suitable for the production of an antibody or an antigen-binding fragment thereof, most preferably a 293 cell or a CHO cell.

16. 19. A method for producing an anti-PD-L1 antibody or antigen-binding fragment thereof, comprising incubating a host cell according to claim 15 under conditions suitable for expression of a nucleic acid encoding the anti-PD-L1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 12, and optionally isolating said antibody or antigen-binding fragment thereof; and optionally further comprising recovering said anti-PD-L1 antibody or antigen-binding fragment thereof from said host cell.

17. An immunoconjugate comprising the anti-PD-L1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 12 and an additional substance such as a cytotoxic agent.

18. A pharmaceutical composition comprising the anti-PD-L1 antibody or antigen-binding fragment thereof of any one of claims 1 to 12 or the immunoconjugate of claim 17, and optionally auxiliary pharmaceutical materials.

19. A pharmaceutical composition comprising an anti-PD-L1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 12 or an immunoconjugate according to claim 17, an additional therapeutic agent, and optionally a pharmaceutical auxiliary material; preferably, said additional therapeutic agent is selected from the group consisting of a chemotherapeutic agent, another antibody (e.g., an anti-LAG-3 antibody, e.g., an anti-LAG-3 antibody that binds to a human antigen, preferably the anti-LAG-3 antibody is humanized), a cytotoxic agent, a vaccine, an anti-infective active agent, or an immunomodulatory agent (e.g., an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule).

20. The anti-LAG-3 antibody is (i) the three heavy chain complementarity determining regions (HCDRs) of the heavy chain variable region set forth in SEQ ID NO: 75, and / or (ii) three light chain complementarity determining regions (LCDRs) of the light chain variable region set forth in SEQ ID NO: 76 20. The pharmaceutical composition of claim 19 comprising:

21. The anti-LAG-3 antibody comprises a heavy chain variable region (VH) and / or a light chain variable region (VL), (i) the VH comprises complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises or consists of the amino acid sequence of SEQ ID NO: 69; the HCDR2 comprises or consists of an amino acid sequence selected from SEQ ID NO: 70; the HCDR3 comprises or consists of the amino acid sequence of SEQ ID NO: 71; and / or (ii) the VL comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3, wherein the LCDR1 comprises or consists of the amino acid sequence of SEQ ID NO: 72; the LCDR2 comprises or consists of the amino acid sequence of SEQ ID NO: 73; and the LCDR3 comprises or consists of an amino acid sequence selected from SEQ ID NO:

74.

20. The pharmaceutical composition of claim 19.

22. Use of an effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof of any one of claims 1 to 12, or an immunoconjugate of claim 17, in the preparation of a medicament for preventing or treating a tumor or an infectious disease in a subject or individual.

23. 20. Use of an effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof of any one of claims 1 to 12, an immunoconjugate of claim 17, or a pharmaceutical composition of claim 18 or 19, and an anti-LAG-3 antibody (e.g., an anti-LAG-3 antibody that binds to a human antigen, preferably the anti-LAG-3 antibody is humanized) in the preparation of a medicament for preventing or treating a tumor or an infectious disease in a subject or individual.

24. 24. The use according to claim 22 or 23, wherein the tumor is a cancer, such as a gastrointestinal tumor, such as a gastrointestinal cancer, such as a colon cancer; or the infectious disease is a chronic infectious disease.

25. 25. The use according to any one of claims 22 to 24, wherein the medicament may be administered in combination with one or more other therapies, such as comprising therapy and / or other therapeutic agents, preferably comprising surgery and / or radiation therapy, or wherein the therapeutic agent is selected from the group consisting of chemotherapeutic agents, cytotoxic agents, vaccines, anti-infective active agents, other antibodies (e.g. anti-LAG-3 antibodies, such as anti-LAG-3 antibodies that bind to human antigens, preferably the anti-LAG-3 antibodies are humanized), or immunomodulatory agents (e.g. activators of costimulatory molecules or inhibitors of immune checkpoint molecules).

26. The anti-LAG-3 antibody is (i) the three heavy chain complementarity determining regions (HCDRs) of the heavy chain variable region set forth in SEQ ID NO: 75, and / or (ii) three light chain complementarity determining regions (LCDRs) of the light chain variable region set forth in SEQ ID NO: 76 The use according to any one of claims 23 to 25, comprising:

27. The anti-LAG-3 antibody comprises a heavy chain variable region (VH) and / or a light chain variable region (VL), (i) said VH comprises complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, wherein said HCDR1 comprises or consists of the amino acid sequence of SEQ ID NO: 69; said HCDR2 comprises or consists of an amino acid sequence selected from SEQ ID NO: 70; said HCDR3 comprises or consists of the amino acid sequence of SEQ ID NO: 71; and / or (ii) the VL comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3, wherein the LCDR1 comprises or consists of the amino acid sequence of SEQ ID NO: 72; the LCDR2 comprises or consists of the amino acid sequence of SEQ ID NO: 73; and the LCDR3 comprises or consists of an amino acid sequence selected from SEQ ID NO:

74. Use according to any one of claims 23 to 25.

28. 1. A method for detecting PD-L1 in a sample, comprising: (a) contacting the sample with an anti-PD-L1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 12; and (b) detecting the formation of a complex of an anti-PD-L1 antibody, or an antigen-binding fragment thereof, and PD-L1, optionally wherein the anti-PD-L1 antibody is detectably labeled. The method comprising:

Citation Information

Patent Citations

  • Application of anti-PD-L1 humanized monoclonal antibody combined with interferon gene stimulating protein (STING) agonist in tumor resistance

    CN106554416A

  • Human antibodies that bind to lymphocyte activation gene-3 (LAG-3) and their use

    JP2012500006A

  • Antibodies and other molecules that bind to B7-H1 and PD-1

    JP2014523401A

  • Compositions and methods for modulating and redirecting immune responses

    WO2015112534A2

  • Anti-PD-l1 antibodies

    WO2016111645A1